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SUMMARY 
Reactivation of polyomaviruses JCV and BKV in immunocompromised patients after 
transplantation results in severe complications related to the central nervous system 
(CNS) and the urogenital system, i.e. progressive multifocal leukoencephalopathy 
(PML) and hemorrhagic cystitis (HC). Anti-viral drug treatment in this situation is not 
effective and therefore cure is largely dependent on the restoration of the immune 
system by tapering out of immunosuppressive drugs. However, restoration of 
immune system post transplantation might lead to graft versus host disease (GvHD). 
Adoptive transfer of virus-specific T cells constitute an alternative would be which 
would avoid the risk of GvHD due to its specific reactivity to virus-infected cells.     
To this end, two previously known immunodominant human leukocyte antigen (HLA)-
A2 restricted epitopes (p36 and p100) derived from VP1 protein were analyzed. We 
observed that the precursor T cell frequency to these two HLA-A2 restricted peptides 
was very low when compared to T cells specific for other viruses (e.g. CMV, 
influenza virus etc.). To efficiently measure polyomavirus-specific T cells in vitro, 
optimization towards increased sensitivity of the expansion protocol and the read-out 
system was performed. Further characterization showed that p100-specific T cells 
were T cells of high avidity. Moreover, in the in vitro culture, virus-specific T cells 
were successfully maintained for a longer period of time (up to 5 weeks) with no loss 
of peptide-specificity and functional reactivity. Additionally, we demonstrated that 
JCV-VP1-peptide-specific T cells were cross-reactive to the BKV-VP1-p108-peptide 
when measured by multi-parametric flow cytometry and functional assays like 
ELISPOT and cytotoxicity assays.  
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In a comprehensive approach to widen our knowledge for new CD8+ TCEs restricted 
to other HLA-types, we used an array of overlapping peptides spanning the whole 
JCV-VP1 protein. Peptides were used in a form of matrix sub-pools and/or as 
individual peptide stimulation. In addition to two known HLA-A2 restricted peptide 
epitopes, several novel T cell specificities were identified in healthy donors (HDs) 
and in a patient. Using VP1-derived virus like particles (VLP) for initial stimulation, it 
was confirmed that all responding peptides were naturally processed. Additionally, a 
restriction analysis was performed for HLA-A2 and HLA-B7 alleles using HLA class I 
transfected lines of K562 and T2 cells as target cells in the immunological assays.  
Taken together, we observed JCV-VP1-specific T cells to two HLA-A2 restricted 
immunodominant peptides of high avidity with sustained peptide-specificity and high 
functional reactivity in long-term cultures. Furthermore, we identified novel, naturally 
processed JCV-VP1-derived CD8+ T cell epitopes (TCEs) restricted to HLA-A2 and 
HLA-B7. This new set of data will broaden the armamentarium of therapeutically 
useful peptides and contribute to the development of T cell immunotherapies against 
polyomavirus-related disease. Our long term goal includes enrichment and isolation 
of polyomavirus-specific T cell specificities for use as adoptive T cell transfer in the 
clinical setting. Cross-reactive T cells have the additional benefit that an appropriate 
immunotherapy can target both polyomaviruses simultaneously. 
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AIM OF THE STUDY 
For JCV and BKV-associated diseases in immunocompromised patients, adoptive T 
cell transfer constitutes an excellent option. To date two immunodominant CD8+ T 
cell epitopes have been identified in HLA-A2 individuals. To provide adoptive T cell 
transfer to patients across all haplotypes, there is a fervent need to identify and 
characterize more T cell epitopes. In the clinical setting, this extended knowledge 
would open new avenues for the efficient development of a comprehensive T cell 
immunotherapy against JCV and BKV infection.   
The specific aim of this study was as follows: 
1) Characterization of immunodominant HLA-A2 restricted JCV-VP1-p100-
peptide-specific T cells.  
2) Characterization of the cross-reactivity between JCV and BKV-peptide-
specific T cells. 
3) Identification of novel, naturally processed HLA-A2 and HLA-B7 restricted 
CD8+ T cell epitopes in healthy donors (HDs) and patients. 
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1 INTRODUCTION 
1.1 Role of cellular immunity in viral infections 
Anti-viral cellular immunity differs from that of humoral immunity which is effective 
through antibodies. These soluble antibodies bind to the complex viral particles and 
can neutralize the infectivity of the virus. Also, antibodies cause viral elimination with 
the help of complement proteins. However, cell-mediated immunity is the most 
relevant mechanism in the control of viral infection or reactivation. With the help of T 
cell receptors (TCRs), T cells recognize virus-infected or-ingested cells and destroy 
these cells. Both CD4+ and CD8+ T cells actively participate in antiviral response. In 
immunocompetent individuals, cellular immunity keeps check on reactivation of 
latent viruses like cytomegalovirus (CMV), Epstein-Barr virus (EBV), adenoviruses, 
polyomaviruses etc.  
The primary induction of cellular immune responses occurs in secondary lymphoid 
organs where antigen presenting cells (APCs) display antigens that are derived from 
viruses to T cells. APCs take up the viral antigens from the initial sites of infection. In 
secondary lymphoid organs, the encounter of naïve T cells with APCs leads to the 
activation of T cells. This results in the initiation of molecular and cellular signals 
including the release of cytokines and inflammatory mediators which are also 
important for the activation of other immune cells. T cells recognize virus-derived 
peptides or proteins only when these are associated with major histocompatibility 
complex (MHC) molecules, in humans also called human leukocyte antigen (HLA) 
molecules. Therefore, induced immune response is highly specific and the 
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magnitude depends greatly on the strength and duration of antigenic stimulation, 
HLA restriction, co-stimulatory signals and help of CD4+ T cells.  
CD8+ T cells are the most important effectors cells of cellular immunity. These cells 
can undergo massive proliferation following virus encounter. CD8+ T cells are 
activated in secondary lymphoid organs and later dispersed throughout the host 
body. Here, they produce inflammatory mediators like interferon-γ (IFN-γ) and tumor 
necrosis factor-α (TNF-α) and cytotoxic molecules (perforin, granzyme B) which kills 
the virus-infected cells before the release of progeny viruses.  
CD4+ T cells are helper T cells because they can help B cells and CD8+ T cells for 
the successful activation of immune response. Additionally, CD4+ T cells produce 
chemokines and cytokines that attract and stimulate other immune cells to the sites 
of infection. Furthermore, CD4+ T cells can act as cytotoxic T cells like CD8+ T cells 
which can directly lyse virus-infected cells.   
The most astonishing feature of T cells is their potential to establish a memory T cell 
pool of virus-experienced cells. These memory T cells, which belong to less than 
10% of the surviving T cells, are long-lived cells which are responsible for the rapid 
response generated during the subsequent attack of same virus. In an ideal 
situation, the memory T cells respond quickly and clear the infection much faster 
than the initial infection.  
1.2 Antigen processing and presentation 
Adaptive immune response starts off with the activation of effector B and T 
lymphocytes by APCs. Both forms of effector lymphocytes identify foreign antigens 
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with the help of highly variable antigen recognition receptors. An antigen to be 
recognized by T lymphocytes needs to be presented along with a specialized 
glycoprotein molecule called HLA class I or class II. Under normal circumstances, 
the origin of the antigen decides to which HLA molecule the peptide will bind and 
eventually which type of T cells (CD4+ or CD8+) will be activated. HLA class I 
molecules binds to the endogenous antigens found in the cytosol and stimulates 
CD8+ T cells, whereas HLA class II molecules binds to the exogenous antigens 
found in intracellular endosomes and stimulates CD4+ T cells (Parkin and Cohen 
2001). For a proper peptide presentation via HLA molecules, native protein has to 
first degrade inside the APCs to a presentable length, a phenomenon referred as 
antigen processing. 
 
Figure 1: Sources of antigen for MHC class I and class II presentation. (Adapted from 
(Trombetta and Mellman 2005). 
1.2.1 MHC/HLA class I antigen presentation 
MHC class I molecule is present in all the nucleated cells and display proteasome 
processed protein antigens in the groove of MHC molecules. In humans, the HLA 
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complex is encoded by chromosome 6 and is extremely polymorphic (York and Rock 
1996). In the absence of peptide antigen, it is stabilized by endoplasmic reticulum 
(ER) chaperone proteins calreticulin, ERp57, protein disulphide isomerase (PDI) and 
chaperone tapasin. Loading of peptides on the HLA molecules includes several 
steps. In the cytosol of APCs, proteins are first tagged by a multi-ubiquitin chain. 
These tagged proteins are recognized by immuno-proteasomes and degraded into 
smaller peptide sequences. The peptides are then transported into the ER lumen 
through the transporter associated with antigen presentation (TAP). Here the 
translocation is done with the help of tapasin, a TAP-associated glycoprotein. In ER, 
unfolded HLA class I molecules are assembled with the peptides and β2-
microglobulin to form folded HLA class I molecule.  
Once peptide binds to HLA molecule, tapasin is released and TAP is recycled for the 
next translocation of peptides to ER. In ER, there are three components which 
provide the stability to HLA class I molecule, a polymorphic heavy chain, a light chain 
(β2-microglobulin) and a peptide of eight to nine amino acids. This complex is now 
transported to the Golgi apparatus and then to the cell surface. In case of no 
assembly with peptides in ER, HLA molecules are recycled to the cytosol for 
degradation (Hughes, Hammond et al. 1997; Koopmann, Albring et al. 2000).  
Due to low affinity of peptides, sometimes MHC class I heavy chains dissociate from 
peptides and then reassemble with exogenous peptides in the presence of serum 
β2-microglobulin (Rocca, Opolski et al. 1992). This effect is referred as cross-
presentation where exogenous antigen peptides are loaded onto MHC class I 
molecules and presented to CD8+ T cells (York and Rock 1996; Li, Haque et al. 
2002; Rock 2006; Vyas, Van der Veen et al. 2008; Knecht, Aguado et al. 2009). This 
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phenomenon is very important in the initiation of an immune response when infection 
(either viral or bacterial) and cancer/leukaemia do not result in the generation of 
endogenous antigens.   
 
Figure 2: MHC/HLA class I processing and presentation. First step of antigen processing and 
presentation is the binding of multi-ubiquitin chain to the antigen. Antigen is then processed in 
proteasome which results in the generation of peptides of 8 to 11 amino acid residues. The peptides 
are transported into the endoplasmic reticulum (ER) by transporter associated with antigen 
presentation (TAP) complex. Within ER, peptides bind to MHC class I heterodimers and peptide-
loaded MHC molecules are then translocated through Golgi apparatus to the cell surface. MHC class I 
molecule loaded with peptide binds specifically to complementary T cell receptors (TCRs) which lead 
to stimulation of CD8+ T cells. (Kloetzel 2001). 
In the groove of a MHC class I molecule, specificities of peptide loading are 
determined by anchor residues. One of the anchor residues is always present in the 
carboxy terminal of the post-proteasomal peptide. Another one or two could be 
present at the amino terminal (Falk, Rotzschke et al. 1991). For an adequate peptide 
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binding to a particular MHC class I molecule haplotype, the anchor residue must bind 
to the specific position defined to a particular haplotype.   
1.2.2 Processing of VP1 protein, VLP 
VLP is derived from one of the viral structural capsid protein VP1. The VP1 
capsomere has the ability for self-assembly with the help of disulphide bonds to form 
the stable VLP (Chang, Fung et al. 1997; Chen, Wang et al. 2001). The assembly of 
VLP was first demonstrated after expressing VP1 protein in E. coli by Salunke et al. 
(Salunke, Caspar et al. 1986). VLP has been shown to display antigenic epitopes 
similar to the native virus. This property has been applied in early diagnosis of viral 
diseases using ELISA (Stolt, Sasnauskas et al. 2003; Viscidi, Rollison et al. 2003; 
Viscidi and Clayman 2006; Zielonka, Gedvilaite et al. 2006; Tolstov, Pastrana et al. 
2009; Touze, Gaitan et al. 2010; Nicol, Touze et al. 2012; Zielonka, Gedvilaite et al. 
2012; Nicol, Robinot et al. 2013) and hemagglutination assay (Zielonka, Gedvilaite et 
al. 2012). Additionally, the absence of genetic material in VLP makes it a safer 
alternative to be used as vaccine (Jennings and Bachmann 2008; Roldao, Mellado et 
al. 2010; Kushnir, Streatfield et al. 2012).  
VLP has been shown to induce both humoral and cellular immune responses (Dorn, 
Lawatscheck et al. 2008; Jennings and Bachmann 2008). The size and the presence 
of natural ligands on the surface of VLP which are similar to the native virus help in 
the efficient uptake of VLP by the APCs, particularly by DCs. Other than professional 
APCs (DCs), peripheral blood mononuclear cells (PBMCs) loaded with JCV-VP1-
VLP have also been used to stimulate T cells (Aly, Yousef et al. 2011).   
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1.3 Immunosuppression and viral infections 
The human immune system is finely balanced to maintain the equilibrium between 
protection from pathogens and tolerance to self-antigens. There are several factors 
that can disturb this equilibrium and hence lower the efficiency of immune 
responses. For example, a state of immunosuppression, that leads to the 
reactivation of various latent viral or bacterial pathogens, which are otherwise 
controlled by the efficient immune system. Immunosuppression can be caused by 
malnutrition, ageing or infection and can also be induced by immunosuppressive 
agents.  
In general, immunosuppression is used in the clinical setting to prevent the host from 
rejecting a transplant or for the treatment of autoimmune diseases. 
Immunosuppression is induced mainly by drugs or radiation. Under 
immunosuppression, opportunistic infections occur due to the reactivation of latent 
viruses in the patients or from the donor organs. Viral reactivation is one of the major 
causes of mortality and morbidity in most of the transplanted patients. The most 
common opportunistic viral pathogen which is reactivated in a transplantation setting 
is CMV. Other viral pathogens like EBV, adenovirus, herpes simplex virus (HSV), 
BKV, and JCV are also reported in a significant number of cases.  
Besides induction through immunosuppressant agents and radiation, 
immunosuppression occurs in the state of malnutrition, ageing or caused by 
infections (HIV or other diseases). HIV related immunosuppression is characterized 
by a progressive depletion of CD4+ helper T cells. This state of immunosuppression 
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is also a major cause for the reactivation of many latent viruses like CMV, EBV and 
JCV (Stoner, Agostini et al. 1998; Bienaime, Colson et al. 2006).  
1.4 JC and BK polyomaviruses 
Human polyomaviruses were first described in the 1950s, when they were identified 
as the causative agents of multiple tumors in rodents, hence the name polyoma 
(“poly” greek for many and the greek suffix “-oma” for tumors) was coined. Simian 
virus-40 (SV-40) was the first primate polyomavirus identified in African green 
monkey kidney cells (Sweet and Hilleman 1960). JC and BK polyomaviruses were 
later described in 1970s. JCV was isolated from brain tissue of a patient with the 
initials “JC” who suffered from PML (Padgett, Walker et al. 1971), and BKV grew in 
cell cultures after inoculation with the urine from a renal transplant recipient with the 
initials “BK” (Sweet and Hilleman 1960). Eight additional human polyomaviruses 
have been identified since 2007.   
1.4.1 Morphology and genome 
Polyomaviruses are small non-envelope particles encompassing the circular double-
stranded deoxyribonucleic acid (DNA) genome. BKV and JCV genomes are 
approximately 5,300 bp and 5,130 bp in size, respectively (Ferenczy, Marshall et al. 
2012). All members of the polyomavirus family share common morphology and 
genome organization. The polyomavirus genome can be divided into three functional 
parts (Figure 3).  
i) The non-coding control region: contains viral promoters and the origin of 
replication.  
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ii) The viral early gene region which encodes the large T-antigen (LT-
antigen) and the small T-antigen (sT-antigen). It is involved in the 
replication of viral genome. 
iii) The viral late gene region which encodes the viral proteins VP1, VP2, VP3 
as well as the agno-protein. It is involved in encoding structural proteins.  
Among all the early and late gene expressing proteins, VP1 is the only protein 
exposed on the surface of the capsid and thus determines the receptor specificity.  
 
Figure 3: Organization of the genome of human polyomaviruses. (Atkin, Griffin et al. 2009). 
1.4.2 Seroprevalence and infection 
The asymptomatic primary contact with polyomaviruses occurs during childhood or 
early adulthood resulting in a lifelong persistence in immunocompetent individuals, 
leading to more than 80% seroprevalence in the adult population worldwide. Initial 
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infections of host cells are facilitated by the interactions of BKV and JCV with 
negatively charged sialic acid containing receptors. In the case of SV-40, 
ganglioside-monosialic acid (GM1) is the major receptor. In addition to sialic acid as 
receptor, the JC virus also uses the serotonin receptor (5HT2AR) to infect glial cells 
(Elphick, Querbes et al. 2004). After primary infection, human polyomaviruses persist 
in the urinary tract, B lymphocytes and the brain (Chesters, Heritage et al. 1983).  
 
Figure 4: Clinical course of human polyomavirus infection. After primary infection JCV and BKV 
can persist in different types of tissue. In the immunocompetent host the polyomaviruses are 
controlled whereas immunodeficient patients are prone to clinically overt infection. 
In case of JCV, infected B cells may carry virus across the blood brain barrier (BBB) 
(Major, Amemiya et al. 1990). Polymerase chain reaction (PCR) and antibody titer 
enzyme-linked immunosorbent assays (ELISA) confirm the presence of concomitant 
infections of JCV and BKV in HIV positive patients, post organ transplant patients, 
pregnant women and few healthy individuals. The pathophysiology of human 
polyomaviruses is explained in Figure 4. 
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1.4.3 JCV-associated complications and diagnosis 
Unlike BKV, the other member of same genus, JCV is never involved in diseases of 
the urogenital tract or the lungs. The most prominent site of JCV-associated 
complications in the immunocompromised host is the central nervous system (CNS). 
Once JCV has entered the CNS, the virus replicates vigorously and leads to PML, a 
lethal disease. PML is a demyelinating disorder characterized by pinhead-sized 
demyelinating lesions in the brain. It occurs in 3-5% of HIV-infected patients, in 
patients suffering from autoimmune disorders, in cancer patients involving the 
lymphoid system (lymphoma), patients on long-term immunosuppressive therapy 
and few elderly patients with involution of the thymus. Previously, PML was 
considered as a rare opportunistic infection, but after the discovery of HIV, 80% of 
PML cases were contributed by HIV patients. The incidences of PML in non-HIV-
infected patients are also increasing for hematologic malignancies (13%), organ 
transplant recipients (5%), and patients with autoimmune disease treated with 
immunomodulators (3%) (Gheuens, Pierone et al. 2010). In PML disease, tissue 
demyelination occurs due to the lytic activity of JCV in oligodendrocytes, which leads 
to the impairment of brain function and eventually to death. However, highly active 
antiretroviral therapy (HAART) in HIV patients has significantly improved the survival 
rate of PML patients (Berger and Houff 2006; De Luca, Ammassari et al. 2008). 
Nevertheless, the mortality associated with PML still approaches >50% within the 
first year (Tassie, Gasnault et al. 1999; Berenguer, Miralles et al. 2003).  
The adverse effects of immunomodulatory therapy and immunosuppression are the 
major reason for immunosuppression leading to JCV-mediated fatal PML cases in 
patients. In immunosuppressed patients, immunomodulatory drugs like fludarabine, 
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methotrexate, cyclophosphamide and monoclonal antibodies like natalizumab (in 
multiple sclerosis and Crohn’s disease), rituximab (in MS, non-HL, RA, SLE, MG 
diseases) etc. are responsible for inhibiting the biological function of immune cells. 
As anti-polyomavirus drugs with clinical efficacy are simply not available, the 
treatment solely relies on improving virus-specific immunity.  
JCV causes PML during immunosuppressive conditions like the following.   
Infections with HIV: The majority of the PML cases have been reported in HIV-1 
patients. A very few cases are also reported in HIV-2 patients (Stoner, Agostini et al. 
1998; Bienaime, Colson et al. 2006). With the advent of HIV treatment, the so-called 
HAART there was a significant improvement in the survival time of PML patients in 
HIV settings (Lewden, May et al. 2008). However, PML is still the second most 
common cause of death (14%) in HIV patients (Lewden, May et al. 2008). 
In the setting of hematologic and oncologic malignancies: JCV-induced PML is also 
associated with lymho-proliferative disorders (Garcia-Suarez, de Miguel et al. 2005), 
like in chronic lymphocytic lymphoma, Hodgkin disease, non-Hodgkin lymphoma and 
multiple myeloma. 
In the setting of stem cell and solid organ transplantations: JCV-reactivation occurs 
in transplantation setting due to the immunosuppressive conditions induced by 
intense immunosuppressive regimen (Shitrit, Lev et al. 2005; Kharfan-Dabaja, Ayala 
et al. 2007).   
In patients with rheumatologic disorder: Systemic lupus erythematosus (SLE) is most 
commonly associated with JCV-induced PML. In other rheumatologic disorders like 
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rheumatoid arthritis, dermatomyositis, polymyositis and scleroderma the incidence of 
PML is rather low.  
During monoclonal antibody (mAb) therapy: mAb treatment is practiced in many 
immunological diseases and few of these antibodies can suppress the immune 
system. For example, antibodies like, efalizumab, rituximab and natalizumab which 
are used in the setting of autoimmune diseases are associated with PML 
(Kleinschmidt-DeMasters and Tyler 2005; Langer-Gould, Atlas et al. 2005; Van 
Assche, Van Ranst et al. 2005; Carson, Focosi et al. 2009).  
Other diseases: Few conditions of no or minimal immunodeficiency like renal failure, 
psoriasis, dermatomyositis etc. are also reported to cause immunosuppression and 
make patients prone to PML (Gheuens, Pierone et al. 2010).  
In PML patients, MRI scans of the brain show the characteristic multifocal areas of 
demyelinating white matter lesions with irregular borders. Other than MRI scans, an 
indirect way of diagnosis is to detect JCV-DNA in the cerebrospinal fluid (CSF) by 
PCR amplification. However, PCR analysis is less sensitive in HIV patients receiving 
HAART (Cinque, Koralnik et al. 2009).   
1.4.4 Adaptive immune responses to the JCV 
1.4.4.1 Humoral immune response 
Humoral immune responses are mediated by certain macromolecules such as 
secreted antibodies and complement proteins. Antibodies are soluble protein 
molecules secreted by B cells that are highly specific to foreign targets called 
antigens. As adults are already exposed to polyomaviruses during their childhood, 
most of them are seropositive for polyomavirus-specific serum antibodies. In most of 
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the viral infections, antibodies serve as neutralizing agents targeting viral proteins 
and facilitate the elimination of viruses by phagocytic cells. In polyomavirus-reactive 
patients, elevated antibody titers are seen only after the decrease of viral load 
(Comoli, Azzi et al. 2004; Hariharan, Cohen et al. 2005; Chen, Trofe et al. 2006), 
which suggests a role of CD4+ T helper cells in stimulating B cells to differentiate into 
plasma cells. These antibodies are not effective in controling the polyomavirus-
associated complications, but they may be effective in controling viremia. 
Approximately 60-90% of the world population is seropositive to JCV and 19-27% of 
healthy individuals shed JC virions in the urine (Walker and Padgett 1983; 
Markowitz, Thompson et al. 1993; Egli, Infanti et al. 2009). Although the majority of 
the population is positive, a very small fraction of these individuals progress to PML 
disease mostly due to immunosuppressive changes in their immune system. Overall, 
the JCV-specific humoral immune response has not been shown to control JCV-
infection effectively (Weber, Goldmann et al. 2001; Koralnik 2002). Also the nature of 
JCV to remain intra-nuclear after viral assembly seems to help in the viral escape 
from immune recognition.   
1.4.4.2 Cellular immune response 
Cellular immunity, the other branch of adaptive immunity comes in play when 
infectious virions enter host cells. Polyomavirus-specific responses mostly belong to 
this branch of the immune system, comprising extensively studied T cells. Studies in 
a mouse model of polyomavirus infection (Lukacher and Wilson 1998) and as well as 
observations in patients showed that the cytotoxic T lymphocyte (CTL) response has 
a strong correlation to disease outcome in the case of both JCV and BKV (Li, 
Melenhorst et al. 2006; Binggeli, Egli et al. 2007). 
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CD8+ T cells (Du Pasquier, Clark et al. 2001; Koralnik, Du Pasquier et al. 2001; 
Wuthrich, Kesari et al. 2006; Lima, Marzocchetti et al. 2007; Lima, Bernal-Cano et al. 
2010) as well as CD4+ T cells (Gasnault, Kahraman et al. 2003; Aly, Yousef et al. 
2011) have been shown to be effective in the control of JCV infection. The advent of 
HAART in HIV patients reduced the rate of PML which indirectly strengthens the 
overall immune response by reconstituting T cell responses (Albrecht, Hoffmann et 
al. 1998; Engsig, Hansen et al. 2009). In these patients, HAART has no direct effect 
on the replication of JCV but seems to be effective against JCV by limiting HIV 
replication.        
1.4.5 Treatment of polyomavirus disease 
So far, therapeutic approaches for PML have shown less or almost no significant 
clinical impact (Tavazzi, White et al. 2012). This could be due to the BBB which 
makes the CNS less accessible to chemical drugs. Nevertheless, a few clinical 
studies showed an improvement of clinical neurological symptoms and findings in 
the MRI after administration of risperidone (Focosi, Kast et al. 2007), mitrazapine 
(Owczarczyk, Hilker et al. 2007; Verma, Cikurel et al. 2007; Cettomai and McArthur 
2009) and recombinant IL-2 (Przepiorka, Jaeckle et al. 1997; Kunschner and Scott 
2005). One drug, cidofovir showed clinical impact in BKV-induced HC patients, 
however no significant clinical effect was reported on the survival of PML patients 
(Marra, Rajicic et al. 2002; Pohlmann, Hochauf et al. 2007; De Luca, Ammassari et 
al. 2008; Kraemer, Evers et al. 2008). In contrast to that, an immunotherapeutic 
approach showed some promise: Here a patient with the clinical status of JCV-
associated PML greatly improved and showed a complete clearance of JCV-DNA in 
the cerebrospinal fluid after the adoptive transfer of JCV-specific in vitro activated 
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CTLs (Balduzzi, Lucchini et al. 2011). In summary, there are no clear guidelines for 
the drug treatment of JCV-related infection or reactivation and successful therapy 
depends greatly on the overall improvement of immune system. For example, in 
patients with PML, HAART improves the overall immune system hence it is the only 
therapy which seems to have an effective clinical outcomes. 
1.5 Adoptive immunotherapy 
Viral infection during immunosuppression is a major complication in transplantation, 
rheumatologic, and other immunodeficient condition (HIV). For the successful 
eradication of viral infection, anti-viral therapies are a pre-requisite. Anti-viral 
therapies post immunosuppression falls into 3 strategic categories:  
i) A prophylactic therapy, also called as preventive therapy is administrated before 
an active viral infection occurs. 
ii) A pre-emptive therapy applied at the stage of infection with sensitive and rapid 
monitoring methods while still no disease could be diagnosed.  
iii) A curative therapy applied after establishment of viral disease. This comprises 
mostly anti-viral drug therapy.  
Anti-viral drugs are effective to combat viral infection or reactivation. However, these 
drugs are not very effective in the total elimination of latent viral reservoir and the 
impact on the overall survival of patients is still questioned. Moreover, due to the 
disadvantages like costs, toxicity, drug-resistant mutants and the risk ofr secondary 
infections, there is a fervent need of other therapeutic strategies/approaches. 
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Immunotherapy is one effective approach which is defined as the treatment of 
disease by manipulating the immune system of patients (Figure 5).  
 
Figure 5: Overview of antigen-specific immunotherapeutic strategies. (Adapted from (Van den 
Bosch, Ponsaerts et al. 2006) 
Immunotherapeutic approaches have been evolved from infusion of non-antigen-
specific T cells, a donor lymphocyte infusion (DLI) to the selection and isolation of 
antigen-specific T cells during the past few decades. During DLI, a large number of 
donor T cells are also transfused into the host. Although these mature T cells are 
responsible for the protection against infectious diseases, they are also largely 
responsible for the unintended graft versus host disease (GvHD). To overcome this 
problem one option is to reconstitute the immune system by the adoptive transfer of 
donor T cells. This should be performed after few weeks or months from 
transplantation, in order to reduce the risk of GvHD. Moreover, when adoptive 
transfer is performed using peptide epitope-specific T cells the risk of GvHD is 
almost nil.  
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Study by Riddell and Greenberg’s group showed for the first time a successful 
adoptive transfer of CMV-specific T cells in the setting of hematopoietic stem cell 
transplantation (HSCT) (Riddell, Watanabe et al. 1992). Here T cell lines were 
transfused between 28 and 42 days after transplantation. A highly CMV-specific 
cytotoxicity was observed in all patients in this study, and in few patients it reached 
the same as the donor. Some other studies also showed the successful adoptive 
transfer of CMV (Walter, Greenberg et al. 1995; Einsele, Roosnek et al. 2002; 
Peggs, Verfuerth et al. 2003) and EBV (Papadopoulos, Ladanyi et al. 1994; Rooney, 
Smith et al. 1995; Rooney, Smith et al. 1998; Haque, Wilkie et al. 2002)-specific T 
cells after transplantation.  
Progress in flow cytometry and the advent of multimers facilitates monitoring and 
isolation of viral-specific T cells with high purity and either directly from PBMCs or 
expanded T cells. A study by Cwynarski et al. showed for the first time quantification 
of reconstituted CMV-specific T cells by MHC-tetramers in patients after allogeneic-
SCT (Cwynarski, Ainsworth et al. 2001). In a classical pioneer study, Cobbold et al. 
demonstrated enhanced immune reconstitution and clearance of the infection in 8 
out of 9 patients who had undergone transfer of MHC-tetramer/magnetically isolated 
CMV-specific CD8+ T cells (Cobbold, Khan et al. 2005).  
More recently, both the introduction of multimers (like streptamers, pentamers etc.) 
and the IFN-γ capture assay facilitated the isolation of good manufacturing practice 
(GMP) grade virus-specific T cells. Some studies showed the successful isolation by 
IFN-γ capture assay and consecutive transfusion of functional T cells specific for 
CMV (Feuchtinger, Opherk et al. 2010; Peggs, Thomson et al. 2011), EBV 
(Moosmann, Bigalke et al. 2010) and adenovirus (Feuchtinger, Richard et al. 2008) 
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in the clinical setting. Schmitt et al. showed for the first time CMV-specific adoptive 
immunotherapy using streptamer isolation (Schmitt, Tonn et al. 2011). In humans, 
adoptive immunotherapy also includes administration of TCR-transfected PBMCs. In 
this context, Yang et al. generated TCR-transfected anti-JCV T cells (specific to VP1, 
p36 and p100; two HLA-A2 restricted immunodominant peptides) (Yang, Beaudoin et 
al. 2007).  
In the case of JCV-associated infections, a single case study using JCV-specific T 
cells as adoptive T cell therapy has been reported (Balduzzi, Lucchini et al. 2011). 
Here, JCV-stimulated T cells were not single-epitope-specific rather, PBMCs were 
expanded using 15mer peptide pool of entire JCV-VP1 and LT-antigen proteins.  
For an effective antigen-specific immunotherapeutic strategy, the knowledge of HLA-
restriction and selection of a potent immunogenic peptide antigen is the most critical 
step. In this context, the availability of overlapping matrix peptide pool is an excellent 
tool for the selection of immunodominant epitopes across the viral genome. As a 
different approach, advanced knowledge about HLA class I and II gives an added 
advantage to use more sophisticated strategy to identify HLA-binding motifs 
(discussed in 1.8.1.3). This latter bioinformatics-based prediction approach follows 
excellent prediction protocols but needs an experimental confirmation of epitope 
immunogenicity. By employing one or both approaches, some BKV and JCV-specific 
peptide epitopes have been mentioned in earlier reports (Table 1)  
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Table 1: Studies reporting BKV and JCV-specific HLA-A2 restricted peptide sequences. (#HLA-
B0702 and B08 restricted). 
BKV/JCV peptide sequence  References 
BKV-VP1-p44 AITEVECFL 
JCV-VP1-p36 SITEVECFL 
Chen, Y., et al (2006); Lima, M.A., et al (2007); Sharma, M.C., et al (2006); van 
Aalderen, M.C., et al (2013); Du Pasquier, R.A., et al (2004); Zhou, W., et al (2007); 
Yang, W., et al (2007); Marzocchetti, A., et al (2009); Du Pasquier, R.A., et al (2006); Du 
Pasquier, R.A., et al (2005); Tan, C.S., et al (2013) 
BKV-VP1-p108 LLMWEAVTV 
JCV-VP1-p100 ILMWEAVTL 
Chen, Y., et al (2006); Lima, M.A., et al (2007); Sharma, M.C., et al (2006); van 
Aalderen, M.C., et al (2013); Du Pasquier, R.A., et al (2004); Zhou, W., et al (2007); 
Schneidawind, D.,et al (2010); Yang, W., et al (2007); Marzocchetti, A., et al (2009); Du 
Pasquier, R.A., et al (2006); Du Pasquier, R.A., et al (2005); Tan, C.S., et al (2013); 
Koralnik, I.J., (2002); Yang, W., et al (2006); Koralnik, I.J., et al (2002) 
BKV-T-p579 LLLIWFRPV  Randhawa, P.S., et al (2006); Provenzano, M., et al (2006); van Aalderen, M.C., et al 
(2013); Zhou, W., et al (2007); Chen, Y., et al (2008) 
BKV-T-p570 ILQSGMTLL Provenzano, M., et al (2006); Chen, Y., et al (2008) 
BKV-T-p398 CLLPKMDSV Provenzano, M., et al (2006); Chen, Y., et al (2008) 
BKV-T-p410 FLHCIVFNV Randhawa, P.S., et al (2006); Provenzano, M., et al (2006); van Aalderen, M.C., et al 
(2013); Chen, Y., et al (2008) 
BKV-T-p362–371 MLTERFNHIL Randhawa, P.S., et al (2006); Provenzano, M., et al (2006); Zhou, W., et al (2007) 
BKV-T-p406–414 VIFDFLHCI Randhawa, P.S., et al (2006); Provenzano, M., et al (2006); Zhou, W., et al (2007) 
BKV-VP1-p27 LLIKGGVEV Chen, Y., et al (2006); Schneidawind, D.,et al (2010) 
BKV-VP1-p245 LLDEQGVGPL Schneidawind, D.,et al (2010) 
BKV-VP1-p62 NLRGFSLKL Schneidawind, D.,et al (2010) 
BKV-VP1-p90 STARIPLPNL Schneidawind, D.,et al (2010) 
BKV-T-p10 SMELMDLLGL Schneidawind, D.,et al (2010) 
BKV-T-p125 FLRKEPLVWI Schneidawind, D.,et al (2010) 
BKV-T-p4 VLNREESME            
JCV-T-p4 VLNREESME 
Schneidawind, D.,et al (2010) 
BKV-VP1-p84 KMLPCYSTA Chen, Y., et al (2006) 
BKV-VP1-p128 NLHAGSQKV Chen, Y., et al (2006) 
BKV-VP1-p259 SLYVSAADI Chen, Y., et al (2006) 
BKV-T-p313 PYHFKYHEKHFANAI Ramaswami, B., et al (2011) 
BKV-T-p216 KLCTFSFLI Provenzano, M., et al (2006) 
BKV-T-p199 FLTPHRHRV Provenzano, M., et al (2006) 
BKV-T-p176 KLMEKYSVT Provenzano, M., et al (2006) 
BKV-T-p157 TLACFAVYT Provenzano, M., et al (2006) 
BKV-T-p558 SLQNSEFLL Provenzano, M., et al (2006) 
BKV-T-p395 WLHCLLPKM Provenzano, M., et al (2006) 
BKV-T-p436 TLAAGLLDL Provenzano, M., et al (2006) 
BKV-T-p472 VVFEDVKGT Provenzano, M., et al (2006) 
# BKV-T-antigen LPLMRKAYL       
# JCV-T-antigen IPVMRKAYL 
Li, J., et al (2006) 
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1.6 Characterization of novel T cell epitopes (TCEs) 
T cell epitope (TCE) is a peptide sequence which is derived from an antigen, binds to 
HLA molecule and can elicit an immunogenic T cell response. In order to be an 
authentic CD8+ TCE, peptide has to be naturally processed inside the APCs. Epitope 
mapping is a process of identifying T cell determinants or TCE-specific to particular 
HLA restricted peptides from a relevant protein of pathogen. It is a crucial step in the 
development of peptide or T cell-based immunotherapies.  
1.6.1 Strategies for T cell mapping 
1.6.1.1 Overlapping peptides 
In order to map all the epitopes derived from the protein of a potential pathogen, 
peptides of 15-18mers overlapped by 11 amino acids are most commonly used. Due 
to the overlapping of amino acid sequences, it has an advantage of not missing any 
antigenic determinants or epitopes. Although, it is well known that the peptide length 
of 8 to 10 amino acids can stimulate an optimal CD8+ T cell responses, 15mer 
peptides are also shown to trigger CD8+ T cell responses in a comparable manner 
(Kiecker, Streitz et al. 2004).  
1.6.1.2 Peptide matrices 
To save the samples or cells, peptide matrices have been introduced (Kern, Bunde 
et al. 2002). Peptide matrix contains grid of peptide sub-pools arranged horizontally 
and vertically (Figure 13). In a matrix pool each peptide is contained in two different 
peptide sub-pools. So when a particular peptide is recognized in the whole set, two 
peptide sub-pools containing the same peptide will be positive. In case, when more 
than two sub-pools are positive, there is a need of further testing to recognize the 
1. INTRODUCTION 
22 
 
targeted peptide. Peptide matrix approach is particularly useful when the cell number 
is limited.  
1.6.1.3 In silico approach  
Many computer algorithm software programs have been developed for the prediction 
of MHC class I and II epitope peptides in the last two decades (Roberts, Meister et 
al. 1996; Rammensee, Bachmann et al. 1999; De Groot, Bosma et al. 2001; Martin, 
Sbai et al. 2003; Bui, Schiewe et al. 2006). These prediction programs are based on 
binding affinity, cleavage sites and TAP-binding peptides. Prediction programs are 
faster, cheaper and can be used to delete non-HLA binding peptides thus increasing 
the possibilities of potential epitopes in a peptide library. Since algorithm protocols 
are based on assumptions and because of the complexity and vastness of HLA 
molecule, in silico predicted epitopes should be also experimentally confirmed in in 
vitro “wet bench” experiments.     
1.6.2 Methods used for T cell epitope mapping: 
a) HLA-peptide multimers: Multimers are complexes made of specific HLA 
class I or class II alleles bound to a specific peptide. Additionally, this 
construct can be visualized in flow cytometry when tagged with a 
fluorochrome. Multimers are easy-to-use tools and precise. They can be 
combined with many other phenotypic or intracellular markers for fine 
characterization of peptide-specific T cells. In order to assign multimers for 
epitope mapping, prior knowledge of HLA-binding peptides is necessary. This 
makes it difficult to use multimers for the identification of new epitopes. To this 
direction, a novel approach based on reversible peptide-binding on HLA class 
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I allele was proposed for epitope mapping (Toebes, Coccoris et al. 2006). 
Here, HLA-allele with peptide is first dissociated using ultra-violet (UV) and 
then competitively replaced by a second new peptide with the same HLA-
binding capability but of different specificity. Thus, a new specificity can be 
recognized from a set of peptides. Although, the approach of MHC-peptide 
multimers is attractive, the availability of few HLA-alleles limits its use for all 
known human haplotypes.  
b) Enzyme-linked immunospot (ELISPOT): ELISPOT is based on the 
detection of secreted cytokines or any other effector molecules (e.g. 
granzyme B) when T cells are stimulated specifically or non-specifically. This 
procedure can be used for the measurement of the clonal size and the 
functional property of low-frequency antigen-specific T cells. In an ELISPOT 
assay, a single dot represents one cytokine-secreting cell. Thus it is easy to 
quantify the number of cells secreting a given cytokine. It is also possible to 
simultaneously detect two different cytokines from a single cell using different 
detection reagents (Wolfl, Kuball et al. 2007). ELISPOT is easy, requires 
simple instrumentation and is widely used for epitope mapping. 
c) Intracytoplasmic cytokine staining (ICS): In principle, this approach is 
similar to that of cytokine secretion assessed in ELISPOT assays. However, 
here the cytokines are retained inside the cell using a reagent which inhibits 
the secretion of cytokines from Golgi apparatus outside the cell. After 
permeabilization with a detergent, trapped cytokines are stained with 
fluorochrome-conjugated antibodies and visualized by flow cytometry. The 
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advantage of ICS is that it can be combined with many phenotypic markers or 
other secreting cytokines in a multiparametric flow cytometric setting. 
d) Lympho-proliferation: Lympho-proliferation relies on the proliferation of 
antigen-specific T cells. In this context, radioactive like 3H-thymidine uptake 
assay and non-radioactive like carboxyfluorescein succinimidyl ester (CFSE) 
constitute commonly used approaches for epitope mapping. Since lympho-
proliferation assays are not indicators for the functional aspects of proliferative 
cells, this approach has been mostly used for initial pre-screening or has been 
combined with ICS for epitope mapping (Tesfa, Volk et al. 2003). 
e) Solid phase HLA-peptide complexes: It constitutes an approach in which 
solid phase HLA-peptide complexes can be used to recognize and select 
specific T cells.  
f) Other methods: Methods like cytokine-capture/secretion assay or 
measurement of activation markers (CD154, CD137 etc.) on antigen-specific 
activated T cells are also used as an epitope mapping strategy. 
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2 MATERIAL AND METHODS 
2.1 MATERIAL 
2.1.1 Plasticware 
BD Falcon®, polystyrene, round-
bottom tube 
Cat. No. 352054, BD biosciences, Heidelberg, Germany 
CELLSTAR® 24 well culture plate Cat. No. 662160, Greiner Bio-One, Frickenhausen, 
Germany 
CELLSTAR® polypropylene tubes, 50 
ml 
Cat. No. 227 261, Greiner Bio-One, Frickenhausen, 
Germany 
CELLSTAR® polypropylene tubes, 15 
ml 
Cat. No. 188 271, Greiner Bio-One, Frickenhausen, 
Germany 
CELLSTAR® serological pipettes, 2 ml Cat. No. 710 180, Greiner Bio-One, Frickenhausen, 
Germany 
COMBITIPS BIOPUR plus, 5.0 ml Cat. No. 0030.069.455, Eppendorf, Hamburg, Germany 
Cryos™ freezing tubes, 2 ml Cat.-No.122277, Greiner Bio-One, Frickenhausen, 
Germany 
Multiply µstrip (PCR tubes) Cat.-No. 72.991.002, Sarstedt, Nümbrecht, Germany 
Disposable protective gloves, M Sempermed, Wien, Austria 
Disposable-scalpel Cat. No. 5205052, Feather, Japan 
Eppendorf T.I.P.S. standard 50-1000 µl Cat. No. 0030 000.919, Eppendorf, Hamburg, Germany 
High-quality pipette tips in bags, racks, 
and space-saving system packaging, 
200 µl 
Cat. No. 70.1130.600, Sarstedt, Nümbrecht, Germany 
High-quality pipette tips in bags, racks, 
and space-saving system packaging, 
10 µl 
Cat. No. 70.760.501, Sarstedt, Nümbrecht, Germany 
MS columns Cat. No.130-042-201, Miltenyi Biotec, Bergisch -
Gladbach, Germany 
Multi-screen-IP, 0.45 µm, clear, sterile Cat. No.MAIPS4510, Millipore, Darmstadt, Germany 
Nunclon™ treated flask, 75 cm2 Cat. No. EW-01930-49, Nunc, Denmark 
Pasteur capillary pipette, 150 mm and 
230 mm 
W.U. Mainz, Germany 
Petri dish, round, with 2 compartments Cat. No. 82.1195, Sarstedt, Nümbrecht, Germany 
Pre-separation filter, 30 µm Cat. No. 130-041-407, Miltenyi Biotec, Bergisch -
Gladbach, Germany 
Serological pipettes, 5 ml Cat. No. 86.1253.001, Sarstedt, Nümbrecht, Germany 
Serological pipettes, 10 ml Cat. No. 86.1254.001, Sarstedt, Nümbrecht, Germany 
Serological pipettes, 50 ml Cat. No. 86.1685.001, Sarstedt, Nümbrecht, Germany 
Tips without filter, 1000 µl Cat. No. 70.762.200, Sarstedt, Nümbrecht, Germany 
Transfer pipette, 3.5 ml Cat. No. 86.1171.001, Sarstedt, Nümbrecht, Germany 
Tube for FACScan flow cytometer 5 ml 
(75x12 mm, PP) 
Cat. No. 551578, Sarstedt, Nümbrecht, Germany 
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2.1.2 Medium, Solutions and buffers 
autoMACS rinsing solution Cat No. 130-091-222, Miltenyi Biotec, Bergisch -
Gladbach, Germany 
Cell staining buffer Cat No. 420201, Biolegend, San Diego, CA, USA 
Distilled water Cat No. 10977-035, Gibco, Grandisland, NY. USA 
DPBS (1X) Cat No. 14190-169, Gibco, Grandisland, NY. USA 
Fetal bovine serum "GOLD" Cat. No. A15-151, PAA, Linz, Austria 
FicoLite-H (Human); Sterile filtered Cat No. GTF1511YK, LINARIS, Dossenheim, 
Germany 
MACS BSA stock solution Cat No. 130-091-376, Miltenyi Biotec, Bergisch -
Gladbach, Germany 
RPMI medium 1640 (1X) Cat No. 21875-034, Gibco, Grandisland, NY. USA 
Trypan blue solution Cat No. T8154-20ML, Sigma Aldrich, Steinheim, 
Germany 
Complete RPMI1640 medium Containing 1% penicillin/streptomycin,1% L-
glutamine and 10% fetal bovine serum 
 
2.1.3 Solutions, buffers and antibodies for ELISPOT 
BCIP®/NBT liquid substrate system Cat No. B1911-100ML, Sigma Aldrich, Steinheim, 
Germany 
BD™ ELISPOT AEC substrate set Cat No. 551951, BD Biosciences, Heidelberg, 
Germany 
AEC substrate Cat No. 51-2577KC, BD Biosciences, Heidelberg, 
Germany 
AEC chromogen Cat No. 51-2578KC, BD Biosciences, Heidelberg, 
Germany 
Blocking solution for granzyme B RPMI1640 complete culture medium 
Blocking solution for INF-γ PBS + 10 % FBS 
Human granzyme B ELISPOT set Cat No. 552572, BD Biosciences, Heidelberg, 
Germany 
Granzyme B capture-antibody Cat No. 51-9000058, BD Biosciences, 
Heidelberg, Germany 
Granzyme B detection-antibody Cat No. 51-900060, BD Biosciences, Heidelberg, 
Germany 
Granzyme B streptavidin-HRP Cat No. 51-9000209, BD Biosciences, 
Heidelberg, Germany 
Human IFN-γ ELISpot kit (ALP) Cat No. 3420-2A, Mabtech AB, USA 
Human IFN-γ coating mAb 1-D1K; purified, 
250 µg 
Cat No. 3420-3-250, Mabtech AB, USA 
Human IFN-γ detection mAb (7-B6-1-biotin) Cat No. 3420-6-250, Mabtech AB, USA 
Streptavidin ALP (alkaline phosphatase) Cat No. 3310-8, Mabtech AB, USA 
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2.1.4 Antibodies and tetramers for flow cytometry 
APC anti-human CD137 (4-1BB) antibody Cat No. 309810, Biolegend, San Diego, CA, USA 
APC anti-human CD8 (SK1) antibody Cat No. 344722, Biolegend, San Diego, CA, USA 
APC mouse anti-Human IFN-γ Cat No. 554702, BD biosciences, Heidelberg, 
Germany 
APC mouse IgG1, κ isotype control Cat No. 554681, BD biosciences, Heidelberg, 
Germany 
CMVpp65 MHC-tetramer APC HLA-A*0201 tetramers CMVpp65 495-503 
(NLVPMVATV) APC, LICR, Lausanne, 
Switzerland 
CMVpp65 MHC-tetramer PE HLA-A*0201 tetramers CMVpp65 495-503 
(NLVPMVATV) PE, LICR, Lausanne, Switzerland 
JCV-VP1-p100 MHC-tetramer PE HLA-A*0201 tetramers JCV-VP1-p100-108 
(ILMWEAVTL) PE, LICR, Lausanne, Switzerland 
JCV-VP1-p36 MHC-tetramer PE HLA-A*0201 tetramers JCV-VP1-p36-P44 
(SITEVECFL) PE, LICR, Lausanne, Switzerland 
BKV-VP1-p108 MHC-tetramer PE HLA-A*0201 tetramers BKV-VP1-p108-117 
(LLMWEAVTV) PE, LICR, Lausanne, Switzerland 
FITC anti-human CD8 (SK1) antibody Cat No. 345772, BD biosciences, Heidelberg, 
Germany 
FITC anti-human HLA-A2 (BB7.2) antibody Cat No. 343304, Biolegend, San Diego, CA, USA 
FITC mouse IgG1, κ isotype control Cat No. 555748, BD biosciences, Heidelberg, 
Germany 
PE anti-human CD137 (4-1BB) antibody Cat No. 309804, Biolegend, San Diego, CA, USA 
PE mouse IgG1, κ isotype control Cat No. 555749, BD biosciences, Heidelberg, 
Germany 
Unconjugated HLA-A1, A36 antibody Cat No. 0289HA, One lambda, CA, USA 
FITC, HLA-B7, 27 antibody Cat No. FH1453, One lambda, CA, USA 
FITC, HLA-B8 antibody Cat No. FH0536A, One lambda, CA, USA 
 
2.1.5 Reagents and chemicals 
Autopure 100% isopropanol reagent  Cat No. 949016, QIAGEN, Maryland, USA 
CD8 microbeads, human Cat No. 130-045-201 Miltenyi Biotec, Bergisch-
Gladbach, Germany 
Dimethyl sulfoxide Cat No. D5879-100ML Sigma Aldrich, Steinheim, 
Germany 
di-Sodium hydrogen phosphate 
dihydrate (Na2HPO4 · 2 H2O) 
Cat No. 4984.1, Carl Roth, Karlsruhe, Germany 
Ethanol absolute  Cat No. 32205-1L, Sigma Aldrich, Steinheim, Germany 
Human IL-2 (5 µg) Cat No. 130-093-901, Miltenyi Biotec, Bergisch-
Gladbach, Germany 
Human IL-7 (10 µg) Cat No. 130-093-937, Miltenyi Biotec, Bergisch-
Gladbach, Germany 
L-alanyl-L-glutamine (200 mM) Cat No. 0638 W, Biochrom AG, Berlin 
Natriumchloride (NaCl) Cat No. 3957.1, Carl Roth, Karlsruhe, Germany 
Paraformaldehyde Cat No. 158127-100G, Sigma Aldrich, Steinheim, 
Germany 
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Penicillin/streptomycin Cat No. A2213, Biochrom AG, Berlin 
Phytohemagglutinin Cat No. L9017-5MG, Sigma Aldrich, Steinheim, 
Germany 
Saponin Cat No. 47036-50G-F, Sigma Aldrich, Steinheim, 
Germany 
Sodium dihydrogen phosphate 
monohydrate (NaH2PO4 · H2O) 
Cat No. K300.2, Carl Roth, Karlsruhe, Germany 
Staphylococus entertoxin B  Cat No. S9008-1VL Sigma Aldrich, Steinheim, 
Germany 
TRIS Cat No. 4835.2, Carl Roth, Karlsruhe, Germany 
Tween20® detergent, 100ml Cat No. 655204, Merck, Darmstadt, Germany 
Agarose Cat. No. A8963, Applichem, Gatersleben, Germany 
Ethidium bromide 0.025% Cat.-No. HP47.1, Roth, Karlsruhe, Germany 
TrackltTM DNA ladder  Cat.-No. 10488-058, Invitrogen, California, USA 
6x orange DNA loading dye Cat.-No. R0631, Thermo scientific, Wisconsin, USA 
AmpliTaq DNA polymerase Cat. No. M05768, Roche, Basel, Switzerland 
10x PCR Buffer Cat. No. KP2037, Roche, Basel, Switzerland 
 
2.1.6 Equipments 
-80°C Ultra low temperature freezer SANYO Electric biomedical co. ltd, Japan 
Aqualine AL 12 LAUDA, Germany 
Autoclave, Systec VX-150 Systec GmbH, Wettenberg, Germany 
BD FACScan™ Flow Cytometer BD biosciences, New Jersey, USA 
Elispot reader CTL, Bonn, Germany 
Hemocytometer chamber Optik labor, Berlin, Germany 
Heraeus megafuge 16 centrifuge Thermo scientific, Wisconsin, USA 
Heracell 150i CO2 incubators  Thermo scientific, Wisconsin, USA 
Herasafe KS, Class II biological safety 
cabinet 
Thermo scientific, Wisconsin, USA 
Inverse microscope Hund Wetzlar, Wetzlar, Germany 
KERN EG 2200-2NM KERN & Sohn GmbH, Balingen, Germany 
Light microscope  Hund Wetzlar, Wetzlar, Germany 
Liquid nitrogen tank Model 8038 S/N 14830.59 Forma scientific Inc. 
Germany 
Magnetic stirrer Ikamag TRC, Renner GmbH, Ludwigshafen, 
Germany 
Microcentrifuge 5424R Eppendorf, Hamburg, Germany 
MiniMACS™, MultiStand Miltenyi Biotec, Bergisch-Gladbach, Germany 
Mixter, Reax top Heidolph Instruments GmbH & Co. KG, 
Schwabach, Germany 
Mr. Frosty freezing container Thermo scientific, Wisconsin, USA 
Multipette® stream Eppendorf, Hamburg, Germany 
pipetus® Pipette boy Hirschmann Laborgeräte, Eberstadt Germany 
Refrigerator Liebherr, Ochsenhausen, Gemany 
Research® plus 3-packs Eppendorf, Hamburg, Germany 
Research® plus (fixed) 0.1-2.5 µl Eppendorf, Hamburg, Germany 
Research® plus (multichannel) 30-300 µl Eppendorf, Hamburg, Germany 
VACUSAFE (158 320) INTEGRA Biosciences AG, Zizers, Switzerland  
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2720 Thermal cycler Applied Biosystems, California, USA 
PTC0200 DNA engine gradient thermal 
cycler 
MJ research, Inc., Waltham, Massachusetts, USA 
Electrophoresis gel apparatus PEQLAB Biotechnologie GmbH, Germany  
Bio doc analyzer Biometra, Goettingen, Germany 
Electrophoresis power supply (EU231) PEQLAB Biotechnologie GmbH, Germany  
Nanodrop 2000c Thermo scientific, Wisconsin, USA 
 
2.1.7 Primers  
HLA-A2 5’-GTGGATAGAGCAGGAGGGT-3’ (forward) 
5’-CCAAGAGCGCAGGTCCTCT-3’ (reverse)  
HLA-B8 5’-GACCGGAACACACAGATCTT -3’ (forward) 
5’-CCGCGCGCTCCAGCGTG-3’ (reverse) 
HLA-B7  5’-CAAGTGGGAGGCGGCCCGTGA-3’ (forward) 
5’-TGGTACCAGCGCGCTCCAGCT-3’ (reverse) 
HLA-A1  5’-GCGGACATGGCAGCTCAGAT-3’ (forward) 
5’-CGGAGCCCGTCCACGCACC-3’ (reverse) 
CXADR gene (exon 2) 
 
5’-CTGGGCATCTCTTGAGTTTGGA-3’ (forward) 
5’-ACTGGCAAGGTGATGGACACAT-3’(reverse) 
Human β-actin 
 
5’-CTGGGACGACATGGAGAAAA-3’ (forward) 
5’-AAGGAAGGCTGGAAGAGTGC-3’ (reverse) 
Mycoplasma 5’-GGCGAATGGGTGAGTAACACG-3’ (forward) 
5’-CGGATAACGCTTGCGACCTATG-3’ (reverse) 
 
2.1.8 Peptides, peptide pool and proteins 
All the peptides cited or identified from the protein sequences were designated 
according to the position of starting amino acid (e.g. JCV-VP1-p36-44 as p36). All 
the overlapping peptides were designated with the prefix OP (e.g. JCV-VP1 
overlapping peptide 1 as OP1). JCV and BKV-VLP were a kind gift from Prof. Alma 
Gedvilaite (Vilnius University). 
JCV-VP1-p36-44, SITEVECFL GL Biochem (Shanghai) Ltd.; Minhang Shanghai 
and DKFZ, Heidelberg, Germany 
JCV-VP1-p100-108, ILMWEAVTL GL Biochem (Shanghai) Ltd.; Minhang Shanghai 
and DKFZ, Heidelberg, Germany 
BKV-VP1-p108-117, LLMWEAVTV GL Biochem (Shanghai) Ltd.; Minhang Shanghai 
JCV-VP1-p12-20, DPVQVPKLL DKFZ, Heidelberg, Germany 
JCV-VP1-p78-p86, LPCYSVARI DKFZ, Heidelberg, Germany 
JCV-VP1-p83-91, VARIPLPNL DKFZ, Heidelberg, Germany 
JCV-VP1-p113-121, IGVTSLMNV DKFZ, Heidelberg, Germany 
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JCV-VP1-p244-p252, GPLCKGDNL DKFZ, Heidelberg, Germany 
JCV-VP1-p290-298, NPYPISFLL  DKFZ, Heidelberg, Germany 
JCV-VP1-p306-314, TPRVDGQPM  DKFZ, Heidelberg, Germany 
JCV-VP1-peptide pool (OP1 to OP86) * peptides&elephants GmbH, Postdam  
JCV-VP1 overlapping peptides (OP) * peptides&elephants GmbH, Postdam 
JCV-VP1-VLP Dept. of Eukaryote Genetic Engineering, Institute of 
Biotechnology, Vilnius University 
BKV-VP1-VLP Dept. of Eukaryote Genetic Engineering, Institute of 
Biotechnology, Vilnius University 
CMVpp65-p495-503, NLVPMVATV GL Biochem (Shanghai) Ltd.; Minhang Shanghai 
CMVpp65-p492-506,  
LARNLVPMVATVQGQ 
GL Biochem (Shanghai) Ltd.; Minhang Shanghai 
CMVpp65-p417-426, TPRVTGGGAM peptides&elephants GmbH, Postdam 
IMP-p58-66, GILGFVFTL GL Biochem (Shanghai) Ltd.; Minhang Shanghai 
* Detail in supplementary data 
2.1.9 Healthy donors (HDs) 
Buffy coat samples of healthy donors were obtained from Universität Rostock, Blood 
Bank and from the Institut für Klinische Transfusionsmedizin und Zelltherapie (IKTZ), 
Heidelberg, Blood Bank. Informed consent was obtained from all donors. PBMCs 
were separated using Ficoll-hypaque solution (Biochrom, Berlin, Germany). Briefly, 
buffy coat samples were diluted in phosphate-buffered saline (PBS) (Invitrogen, 
Darmstadt, Germany) layered on the dense Ficoll-hypaque separating solution and 
centrifuged at 2,000 revolutions per minute (rpm) for 20 minutes at room temperature 
(RT) without brake. This density gradient centrifugation separated leukocytes from 
other cells forming an interface. Carefully aspirated interface layer were collected in 
a new tube, washed three times with PBS and cryopreserved in 90% heat-
inactivated fetal bovine serum (FBS) and 10% Dimethyl sulfoxide (DMSO) (Sigma-
Aldrich, Steinheim, Germany) solution according to the standard protocol. Cryo-
preserved PBMCs were stored in liquid nitrogen until used.   
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2.1.10 Patient sample 
A patient who had a severe HC almost 10 years back was admitted in University 
Clinic, Heidelberg, due to chronic GvHD of the lung. The patient was treated by 
extracorporeal photopheresis (ECP). After obtaining the patients informed consent, 
the blood sample was drawn and processed for the isolation of PBMCs and cryo-
preserved in liquid nitrogen until used.  
2.1.11 Cell lines 
Stably transfected K562 cell lines for HLA-A1, HLA-A2, HLA-B7 and HLA-B8 were a 
kind gift from Prof. Thomas Woelfel (University of Mainz, Germany). K562 wild type 
(non-transfected) and K562 expressing HLA-A2 allele were also obtained from Prof. 
Stefan Stevanovic (University of Tuebingen, Germany).  
All the cell lines were checked for mycoplasma contamination by PCR before using 
in any experimental assays.  
K562-non-transfected (K562 wild type)  From Prof. Stefan Stevanovic (University of 
Tuebingen, Germany) 
K562-non-transfected (K562 wild type)  From Prof. Thomas Woelfel (University of 
Mainz, Germany) 
K562-non-transfected (K562 wild type)  From Prof. Peter Terness (University of 
Heidelberg, Germany) 
K562-A1 (HLA-A1-transfected K562 cells) From Prof. Thomas Woelfel (University of 
Mainz, Germany) 
K562-A2 (HLA-A2-transfected K562 cells) From Prof. Thomas Woelfel (University of 
Mainz, Germany) 
K562-A2 (HLA-A2-transfected K562 cells) From Prof. Stefan Stevanovic (University of 
Tuebingen, Germany) 
K562-B7 (HLA-B7-transfected K562 cells) From Prof. Thomas Woelfel (University of 
Mainz, Germany) 
K562-B8 (HLA-B8-transfected K562 cells) From Prof. Thomas Woelfel (University of 
Mainz, Germany) 
T2 cells From Dr. med. Michael Hundemer 
(University of Heidelberg, Germany) 
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2.2 METHODS 
2.2.1 Human leukocyte antigen (HLA)-typing of HDs 
Low resolution two digits HLA-typing was done for all the HDs. Briefly PBMCs were 
thawed, counted and either stained with anti-HLA antibodies or processed for PCR.  
2.2.1.1 Typing by antibodies 
Thawed PBMCs were washed, counted and cell pellets were re-suspended in 100 µl 
of FACS buffer (containing PBS with 0.5% BSA and 0.5M EDTA) and stained with 
anti-HLA-A2 (BB7.2, Biolegend, San Diego, CA, USA), HLA-A1, HLA-B7 and HLA-
B8 antibodies with appropriate isotype controls. Antibody staining was performed at 
4°C for 20 minutes in dark. Cells were washed once and then re-suspended in FACS 
buffer followed by flow cytometric analysis.   
2.2.1.2 Typing by single specific primer-PCR (SSP-PCR) 
a) Isolation of DNA from PBMCs:  
Thawed PBMCs were counted and washed once with PBS. The pellet was re-
suspended with a lysis solution containing 4.5 ml of lysis buffer II, 125 µl of 10% SDS 
and 1,100 µl of 5M sodium perchlorate. After 30 seconds of incubation at RT with 
vigorous shaking, 2 ml of 6M NaCl was added to precipitate protein. After another 30 
seconds of incubation at RT, suspension was centrifuged twiced for 5 minutes at 
1,500 g to pellet all the precipitated proteins. Every time clear supernatant was taken 
in new falcon tube. After centrifugation, 8 ml of isopropanol was added to precipitate 
DNA. Precipitated DNA was carefully taken out using glass pipette, washed twiced 
with 70% ethanol and dissolved in 200 µl of sterile H2O at 550C with continuous 
shaking. The concentration and purity of dissolved DNA was determined by the 
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nanodrop 2000c device. All the DNA preparations from PBMCs were more than 90% 
pure.   
b) PCR and gel electrophoresis:  
HLA-types A*02 and B*07 were determined by a PCR-based method using single 
specific primers (SSP) for HLA-A*02 and HLA-B*07. For each tube of PCR (25 µl), 
master mix containing (2.5 µl PCR buffer, 19.8 µl nuclease-free water, 0.5 µl dNTPs, 
1 unit of Taq polymerase) was prepared. No DNA control tubes and test DNA tubes 
were prepared with 1 µl each of nuclease-free water and DNA (100 ng/µl) 
respectively. An appropriate primer set was added in the master mix (see primer 
table).  
SSP-PCR products were electrophoresed in 1 x TBE buffer and 0.05% ethidium 
bromide containing 2% agarose gels. 100 bp molecular weight marker (ladder) was 
used in each row and after every 9 wells to identify positive bands. The gels were 
run for 45 minutes at 100 V and then visualized using UV trans-illuminator.   
2.2.2 Lympho-proliferative assay 
2.2.2.1 Mixed lymphocyte peptide culture (MLPC) 
Thawed PBMCs were washed once with complete medium consists of Roswell Park 
Memorial Institute (RPMI-1640) containing 1% penicillin/streptomycin (Invitrogen 
Gibco, Grand Island, USA) and 1% L-Glutamine (Biochrom AG). Cells were then 
washed with separation buffer containing MACS buffer (AutoMACS rinsing solution, 
Miltenyi Biotec, Bergisch-Gladbach, Germany) and 0.5% bovine serum albumin 
(BSA, Miltenyi Biotec, Bergisch-Gladbach, Germany). CD8+ and CD8- T cells were 
separated as positive and negative fraction through a MACS column (Miltenyi). CD8- 
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cells, which served as APCs were irradiated with 30 Gy and loaded with appropriate 
peptides, peptide pool or proteins. CD8- cells cultured in complete medium without 
any peptide stimulations served as negative control. After 2 hours of peptide loading, 
CD8- cells were co-cultured with CD8+ T cells in a ratio of 4:1 (20x105: 5x105) in 24-
well plates. The ratio of 4:1 for CD8- and CD8+ T cells were also maintained when 
MLPC was done in 96-well plates. Plates were incubated overnight at 37°C, 5% CO2 
and supplemented with 2.5 ng/ml IL-2 (Sigma Aldrich, Steinheim, Germany) and 20 
ng/mL IL-7 (Miltenyi Biotec, Bergisch-Gladbach, Germany). Cells were incubated 
further for 6 more days before harvesting for the specific experimental assays. For 
some assays, cells were restimulated with peptide loaded autologous PBMCs or 
K562 cells each week. Each well was fed with IL-2 and Il-7 every 2-3 days during 
this procedure. 
 
Figure 6: Scheme representing MLPC procedure.  
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2.2.2.2 “Whole PBMC” approach 
PBMCs were thawed, washed with RPMI-1640 containing 1% penicillin/ 
streptomycin (Invitrogen Gibco, Grand Island, USA) and 1% L-Glutamine (Biochrom 
AG) and plated as 25x105/ml each well in a 24-well format plate. Peptides or proteins 
were added directly in the wells containing PBMC. On second day and every 2-3 
days, cells were supplemented with 2.5 ng/ml IL-2 (Sigma Aldrich, Steinheim, 
Germany) and 20 ng/mL IL-7 (Miltenyi Biotec, Bergisch-Gladbach, Germany). After a 
total of 7 days, cells were either harvested and used in experimental assays or 
restimulated with autologous PBMCs or K562 cells.    
2.2.3 CFSE proliferation assay 
CFSE (Invitrogen, Grand Island, NY, USA) was used as a fluorescent cell staining 
dye to monitor lymphocyte proliferation due to its property of progressive halving of 
fluorescence within daughter cells after each cell division. PBMCs were thawed and 
washed twice with PBS to get rid of serum proteins and then stained with 1mM of 
CFSE for 5 minutes at RT with continuous shaking. After 5 minutes medium 
containing serum was added to stop the reaction and cells were washed 3 times with 
complete medium before placing into culture plates. CFSE staining was measured 
with other fluorescent antibodies to observe the proliferation behavior of different 
lymphocyte populations by flow cytometry.   
2.2.4 JCV-specific T cell screening  
For the purpose of detecting JCV-VP1-specific T cells, HDs were screened by IFN-γ 
ELISPOT assay for positive signal using VP1-peptide pool. Briefly, MLPC was 
performed where CD8- cells were loaded with JCV-VP1-peptide pool and after 7 
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days of co-culture with CD8+ T cells, IFN-γ ELISPOT assays were performed. Since 
peptide pool contains pentadecamer length peptides comprising whole VP1-protein, 
it was possible to screen HDs for VP1-specific T cells in a HLA-independent manner.   
2.2.5 ELISPOT assay 
2.2.5.1  IFN-γ secretion assay 
ELISPOT plates (Multiscreen IP 96-well plates, Millipore, Massachusetts, USA) were 
first pre-wet activated by adding 15 µl, 35% ethanol, washed with PBS and then 
coated with anti–human IFN-γ (Mabtech, Nacka Strand, Sweden) re-suspended in 
PBS. Plates were then incubated overnight at 40C. Second day plates were washed 
with PBS to remove unbound antibodies and then blocked with PBS containing 10% 
FBS for 2 hours at RT. Autologous PBMCs and K562 cells loaded with peptides 
were used as target cells. Appropriate negative and positive control wells were 
prepared with complete medium and SEB-stimulation respectively. Effector cells 
from the cultured wells were then co-cultured with peptide loaded target cells in 
ELISPOT plate and incubated at 37°C, 5% CO2 overnight. Third day plates were 
washed with PBS containing 0.05% tween 20 (Sigma-Aldrich) and biotin-linked 
secondary antibody was added in each well followed by 2 hours incubation at RT. 
Again after wash with PBS containing 0.05% tween 20, streptavidin-alkaline 
phosphatase (ALP) or streptavidin-horseradish peroxidase (HRP) was added and 
incubated for 2 hours at RT. Following washes were first done with PBS containing 
0.05% tween 20 and once with PBS subsequently with substrate buffer. Substrate 
solution was prepared, added and reaction was developed for 3 minutes until visible 
spots were detected in positive control wells. Reaction was stopped with tap water 
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and plate was air dried. Visible spots were counted and analyzed using an 
automated ELISPOT reader (CTL, Bonn, Germany).    
 
Figure 7: General scheme representing ELISPOT assay. (Hickling 1998) 
2.2.5.2 Granzyme B secretion assay 
Granzyme B is a serine protease, released by cytoplasmic granules of cytotoxic T 
cells. Granzyme B along with perforin induces cell death in virus-infected cells. 
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Granzyme B secretions assays were performed as described for the IFN-γ ELISPOT 
apart from use of Granzyme B-specific capture and secondary biotinylated antibody. 
2.2.6   Flow cytometry 
2.2.6.1  Surface marker staining  
All the surface marker antibodies were first titrated and optimum concentration was 
used for flow cytometric staining. Briefly, cells were washed with FACS buffer, 
stained for appropriate antibodies and incubated for 20-30 minutes at 40C. In case of 
TCR-specific MHC-tetramers, stained cells were incubated for 45 minutes at RT 
followed by the surface marker staining for 20-30 minutes at 40C. After staining, cells 
were washed with FACS buffer and re-suspended in the same buffer for flow 
cytometric analysis. A minimum of 50,000 events were acquired during acquisition 
and data were further analyzed using flow cytometry analysis software (FlowJo®, 
Tree Star, Inc, USA) and Facs Diva (FACSDiva, BD biosciences).     
2.2.6.2 IFN-γ intracellular staining 
Intracellular staining for IFN-γ was done according to the described protocol by Jung 
et al. (Jung, Schauer et al. 1993). Briefly, cells were restimulated overnight with 
peptides, peptide pool and proteins. After 2 hours, 10 µg/ml brefeldin-A (BFA) was 
also added to each well. Cells were washed with cold FACS buffer and then stained 
for the surface antigens. Cells were washed twice with FACS buffer and fixed using 
500 µl, 4% paraformaldehyde at RT for 5 minutes.  After washing once with 
permeabilization buffer (FACS buffer with 0.1% saponin, Sigma), cells were re-
suspended in permeabilization buffer and incubated at 40C for 30 minutes. After 
washing once with permeabilization buffer, staining was done for 30 minutes at 40C 
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with anti- IFN-γ antibody and isotype control prepared in the same buffer. Cells were 
once washed, re-suspended in FACS buffer and at least 50,000 events were 
acquired during acquisition. Data were further analyzed as previously described.   
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3 RESULTS 
3.1 Characterization of the relative frequency of polyomavirus-
specific T cells in the peripheral blood 
In the peripheral blood of HDs and patients, precursor frequency is described as the 
number of T cells specific for any given antigen. Precursor frequency may vary a lot 
depending on the type of antigens (van Aalderen, Remmerswaal et al. 2013). Recent 
technical advances like MHC-tetramers and cytokine measurement after stimulation 
with synthetic peptides have allowed accurate quantification of the number of CD8+ T 
cells. To augment the T cell response and to increase the read-out sensitivity, 
protocols for T cell expansion are being used. Though, in vitro expanded T cells do 
not represent the real precursor frequencies, they do reflect the relative numbers of 
T cells. 
Here, relative T cell frequencies for polyomaviruses were compared with influenza 
virus and CMV-specific T cells. The latter have been extensively described in the 
literature (Borysiewicz, Graham et al. 1988; Lee, Oelke et al. 2011). Known 
immunogenic peptide sequences for JCV, CMV and influenza virus were used to 
stimulate PBMCs in an expansion protocol. Specific MHC-tetramers were used to 
detect CD8+ T cells in flow cytometric assays.     
We found that the frequencies of polyomavirus-specific T cells were significantly 
lower than that of CMV and influenza virus. Out of eighteen, fifteen HDs (83%) 
showed low frequencies (≤ 0.5%). Noteworthy that at least one donor showed a 
sufficient number (>2%) of CD8+ T cells specific to the JCV-p100-peptide (Table 2). 
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One recently published study showed similar results using immunodominant BKV-
VP1-p108-peptide (van Aalderen, Remmerswaal et al. 2013). Compared to p100, 
even lower numbers of JCV-VP1-p36-specific T cells were measured. In seven HDs 
tested for p36-specific T cells, we found four with no response and rest of the three 
with low percentage of specific T cells (≤0.2) (Table 2).  
Table 2: Relative frequency of JCV, CMV and influenza virus-specific CD8+ T cells. Numbers 
represent the percentage of MHC-tetramer and CD8 double positive T cells. ID represents the last 
three to four digits from the blood bank code for the healthy donors (HDs).  
ID JCV-VP1 
(p36-44) 
JCV-VP1    
(p100-108) 
CMVpp65   
(p495-503)  
CMVpp65  
(p417-426) 
Influenza matrix 
protein (p58-66) 
4148 - 0.07 - - 4.63 
4318 - 0.0 - 6.62 - 
4040 - 0.0 - 51.9 - 
4179 - 0.0 - - 5.14 
895 0.0 0.5 2.1 - - 
5143 0.0 0.0 10 - - 
110 0.1 0.2 - - - 
114 0.2 0.1 - - - 
207 0.2 0.4 0.1 - - 
425 0.0 0.1 - - - 
797 0.0 0.1 - - - 
4410 - 0.2 1.5 - - 
638 - 0.5 53.6 - - 
211 - 1.27 1.37 - - 
711 - 5.4 7.5 - - 
872 - 2.05 2.44 - - 
713 - 0.0 2.55 - - 
771 - 0.56 53.1 - - 
“-“ indicates not tested  
On the other hand, CMV and influenza virus peptide-specific T cells were detectable 
in most of the patients. Using two immunodominant peptides derived from CMVpp65 
restricted to HLA-A2 and HLA-B7, we found that out of twelve, only one donor 
showed <1% of MHC-tetramer positive T cells (Table 2). In three donors, an 
exceptionally high T cell response was measured where more than half of the CD8+ 
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T cells were specific to the CMVpp65-derived peptide (Table 2). Similarly, we also 
found high T cells for IMP-derived peptide. Although, in this study only four donors 
were tested for CMVpp65-peptide (p417-426) and for the IMP-derived peptide, 
results showed that all the donors tested had high relative frequencies of peptide-
specific T cells (Table 2). Based on these results, it is clear that the number of 
circulating polyomavirus-specific T cells in HDs is very low when compared to other 
viruses (e.g. CMV and influenza virus).    
3.2 Strategies 
3.2.1 MLPC versus “whole PBMCs” approach 
As discussed in the previous section, CD8+ T cells specific to polyomaviruses are in 
general very low. To measure this low-frequency of anti-viral T cells, sensitive 
expansion protocols are needed. We compared two protocols using 
immunodominant CMVpp65-peptide (p495-503) in CMV seropositive HDs. First, we 
performed MLPC where autologous CD8+ T lymphocytes and CD8- fraction of 
PBMCs served as responder and stimulator cells, respectively. Secondly, we 
performed “whole PBMCs” approach, where PBMCs were directly loaded with 
peptides without prior separation. This latter approach was compared to MLPC for 
several reasons. It is easy to perform, inexpensive and also time-saving, whereas 
MLPC technique requires expensive tools like microbeads, magnets, columns and 
filters. After a week of culture, CMVpp65-peptide-specific CD8+ T cells were 
visualized by flow cytometry using MHC-tetramers and antibodies directed to CD8 
and CD137. CD137 was used as a marker for functional-activated T cells which has 
shown to be up-regulated uniformly on all responding cells after 24 hours of 
stimulation (Wolfl, Kuball et al. 2007).   
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There was significant T cell stimulations directed to the CMVpp65-peptide using both 
expansion protocols. However, the overall CD8+ T cell responses were clearly higher 
in MLPC as visualized by MHC-tetramer positive CD8+ T cells (Figure 8 A). 
Additionally, relative percentage of CD8+ T cells were also seen to be higher in 
MLPC compare to “whole PBMCs”. It was probably because in MLPC CD8- T cells 
were irradiated therefore did not contributed in the overall proliferation of cells which 
eventually elevated the relative number of CD8+ T cells.    
 
Figure 8: Comparison of MLPC versus “whole PBMCs stimulation”. Phenotype and function of T 
cells were analyzed after MLPC and “whole PBMCs approach” respectively. The experimental read-
out was performed by multicolor flow cytometry. (A) CD8 versus peptide-specific MHC-tetramer 
immunofluorescence: Cells were gated on lymphocytes. (B) CD137 versus peptide-specific MHC-
tetramer immunofluorescence: Cells were gated on CD8+ T cells.  
Using CD137, we also observed that all the tetramer positive CD8+ T cells were also 
CD137 positive, which indicates the functional activity of T cells (Figure 8 B).  
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We also compared both culture approaches using other viral antigens and found 
similar results (data not shown). Overall, for expanding very low frequencies of anti-
viral T cells in an efficient manner, MLPC was shown to be superior compared to 
“whole PBMCs” protocol. 
3.2.2 Optimization of T cell stimulation 
3.2.2.1 Antigen presenting cells (APCs) 
Activation of CTLs requires APCs of certain qualities. First, APCs should not lead to 
a background of non-specific T cell stimulation and secondly, APCs should possess 
a good antigen presenting capability. Additionally, the ratio of APCs to effectors cells 
constitutes a crucial factor which has a direct impact to trigger T cells.  
Here we tried to optimize and standardize our read-out for an efficient T cell 
response using different APCs at various ratios to effector T cells. We compared 
different types of APCs like autologous CD8- T cells, PBMCs, mDCs, T2 cells and 
transfected lines of K562. K562 cells transfected with HLA class I alleles were used 
as APCs in restriction analysis. T cell responses were initiated using the CMVpp65-
derived peptide (p495-503) in a MLPC. The outcome of the stimulation was 
measured by ELISPOT assay and multicolor flow cytometry. 
We observed that autologous cells as well as cell lines did stimulate T cell responses 
in a ratio dependent manner. Autologous PBMCs at a ratio to effector cells of 10:1 
were able to stimulate significant T cell responses with low background (Figure 9). 
Moreover, it was seen that at higher ratios than this, T cell responses were not 
improving, and the background was also very high (data not shown). Using K562-A2 
and T2 cell lines we found that APCs to effector cells ratio of 1:1 is best and 
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triggered a T cell stimulation similar to autologous PBMCs. Additionally, it was 
observed that the negative fraction of CD8+ T cells was not as good as other APCs 
in restimulating T cells. This could be probably the case as these cells went through 
freeze-thaw cycles ≥2 times which made them comparatively less capable in 
presenting peptides to effector cells. For future experiments, CD8- cells were not 
considered anymore for restimulation in ELISPOT assays.  
 
Figure 9: Comparison of APCs: Representation of an IFN-γ ELISPOT assay after MLPC using 
different ratios of autologous PBMCs and CD8- cells, as well as cell lines T2 and HLA-A2-transfected 
K562 cell lines.   
Consequently, autologous PBMCs and cell lines both were shown to be equally 
effective in initiating significant T cell response at certain ratios to effector T cells.    
K562 cells as APCs: 
Furthermore, for the analysis of HLA restriction in an in vitro assay, non-transfected 
and transfected K562 cells were used. K562 cells transfected with HLA-A2 allele has 
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been previously shown to be efficient in stimulating T cells in ELISPOT assays 
(Britten, Meyer et al. 2002).   
We started with the comparison of K562 wild type (non-transfected) and transfected 
cells from two or more sources. Before utilizing the cells in an in vitro assay, K562 
cells and transfectants were analyzed for the absence of HLA class I expression 
(Figure 10 A) and the presence of HLA-A2 (Figure 10 B) allele by flow cytometry. To 
perform restriction analysis, we compared autologous PBMCs with K562 non-
transfected and transfected cell lines in ELISPOT assays using HLA-A2 restricted 
peptide derived from CMVpp65. Here, K562-A2 as well as autologous PBMCs 
served as positive controls. K562 wild type and K562-B8 cells were used as negative 
controls. We found that the CMVpp65-derived peptide which does not bind 
promiscuously across HLA class I molecules, was presented by K562-A2 and 
autologous PBMCs but not by K562 wild type and K562-B8 cells (Figure 10 C). It is 
clear that K562 wild type cells due to lack of HLA class I molecule and K562-B8 due 
to incompatible HLA class I molecule, were unable to bind and present the HLA-A2 
restricted peptide.  
To understand whether K562 cells can efficiently stimulate T cell responses in the 
absence of autologous APCs, we stimulated freshly isolated CD8+ T cells with K562-
A2 and non-transfected K562 cells. It was observed that there was significant T cell 
response stimulated by K562-A2 cells as seen by IFN-γ secretion in ELISPOT assay 
(Figure 10 D).  
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Figure 10: Antigen presentation properties of K562 wild type (non-transfected) and transfected 
cells: (A) Flow cytometric measurement of HLA class I expression on K562 wild type cells versus. (B) 
HLA-A2-transfected K562 cells. (C) Representation of an IFN-γ ELISPOT assay using autologous 
PBMCs, K562 and transfected lines for HLA-A2 and HLA-B8. (D) MLPC followed by an IFN-γ 
ELISPOT assay using K562 wild type versus HLA-A2-transfected K562 cells.     
In conclusion, K562-transfected cells were very suitable tools not only to utilize them 
efficiently as APCs but also to study HLA restriction in an in vitro culture system. 
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3.2.2.2 Peptide length and concentration 
Optimal length of peptide is also one of the crucial factors deciding the magnitude of 
specific T cell response. Short peptides (9-11 amino acids) as well as long peptides 
(15-40 amino acids) can induce CD8+ T cell responses. Short peptides can bind 
directly and can be presented without the need of processing by the HLA class I 
molecule while longer peptides need to be internalized, processed and then 
presented which is efficiently done by more professional APCs (e.g. DCs). Some 
studies showed that longer peptides are more immunogenic compared to short 
peptides (Zwaveling, Ferreira Mota et al. 2002; Sercarz and Maverakis 2003; Bijker, 
van den Eeden et al. 2008). Moreover, in vivo mouse tumor studies showed that the 
extended processing of longer peptide leads to superior induced memory CD8+ T 
cell response than that of shorter peptides (Zwaveling, Ferreira Mota et al. 2002). 
However, the effect of the peptide length on the induced immune response is still 
under current discussion. 
We compared T cell responses induced by CMVpp65-derived immunodominant 
9mer (nonamer) peptide with a 15mer (pentadecamer) peptide which contains 
flanking residues (Figure 11 A). Using both the peptides at same concentration (100 
ng/ml) a MLPC was performed. The experimental read-out was visualized by MHC-
tetramers in flow cytometry. It was observed that both individual 9mer and 15mer 
peptides were able to stimulate a comparable number of peptide-specific CD8+ T 
cells (Figure 11 B). 15mer peptide stimulation of CD8+ T cells indicated that the 
peptide was processed and then presented by APCs on an HLA class I molecule. 
We could also reproduce similar results with the JCV-VP1-p100-peptide (discussed 
in 3.3).   
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Figure 11: Comparison of 9mer versus 15mer induced T cell response. (A) An schematic 
alignment of the 9mer (nonamer) versus 15mer (pentadecamer) peptide derived from CMVpp65-
peptide (p495-503). (B) Representative flow cytometry data after stimulation in MLPC with CMVpp65-
peptide-derived 9mer versus the corresponding 15mer peptide. Cells were visualized being double-
stained with peptide-specific MHC-tetramers and antibody against CD8.  
To assess the importance of concentration of peptides in the setting of MLPC, we 
compared 9mer and 15mer in a concentration dependent manner. Both peptides 
were used at increasing concentrations, starting from 10 ng/ml to 10 µg/ml. We 
observed that both the 9mer and the 15mer peptides were able to stimulate a 
significant T cell response. At a low concentration (10 ng/ml), a strong T cell 
response was initiated using the 9mer peptide. This indicates that the 9mer peptide 
was efficiently presented on HLA class I molecules by APCs which eventually 
resulted in an excellent T cell response. Moreover, it was observed that the short 
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peptide gave a maximum T cell response at 10 ng/ml that could not be augmented 
by higher concentrations of the peptide (Figure 12).  
Compared to the 9mer peptide, the T cell response induced by the 15mer peptide 
was also good. However, at the lower concentration (10 ng/ml) there was a dramatic 
decrease in the number of specific T cells. A possible explanation for the reduced T 
cell number might be that the 15mer peptide was not sufficiently available at this low 
concentration of 10 ng/ml. Keeping in mind the fact that 15mer peptides cannot 
directly bind to the HLA class I molecule and has to go through internalization and 
processing steps followed by presentation.   
 
Figure 12: 9mer versus 15mer peptide, the concentration matters. Four different concentrations 
of CMVpp65-peptide were used: starting from left to right, 10 ng/ml, 100 ng/ml, 1 µg/ml and 10 µg/ml. 
Representative flow cytometry data after stimulation in MLPC with CMVpp65-peptide-derived 9mer 
versus the corresponding 15mer peptide. Cells were visualized being double-stained with peptide-
specific MHC-tetramers and antibody against CD8.  
In summary, both the 9mer and the 15mer peptides are excellent in stimulating a 
CMVpp65-specific T cell response. Only at concentration lower than 100 ng/ml, the 
9mer peptide appears to be superior.          
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3.2.2.3 Peptide matrix sub-pools versus single peptide stimulation 
Overlapping peptides spanning the whole protein is an approach which has been 
used widely to identify T cell responses to more than one peptide antigen, 
independently from HLA restriction. Overlapping peptide sequences consisting of 15 
amino acid residues with 11 amino acid residues overlap have been previously 
shown to stimulate both CD4+ and CD8+ T cell responses (Maecker, von et al. 2001).  
In a comprehensive epitope mapping strategy, we used 86 overlapping peptides 
which covered the 354 amino acid residues of the viral protein JCV-VP1 (Figure 13 
A). These overlapping peptides were arranged in a horizontal and vertical grid to 
make 19 peptide matrix sub-pools. Each peptide matrix sub-pool encompassed at 
least 6 individual overlapping peptides and due to the arrangement each individual 
peptide was present in 2 sub-pools (Figure 13 B). Peptide matrix pools have several 
advantages over individual peptides. The matrix pool approach is useful in 
measuring the immune response when the numbers of immune cells are limited. 
Therefore it reduces the amount of samples required and saves time and reagents.  
To understand whether the matrix peptide pool can initiate a T cell response similarly 
to the 9mer peptide, we compared the T cell stimulation induced by JCV-VP1-p100-
peptide (9mer) with peptide matrix sub-pools encompassing the corresponding 
15mer peptide OP25. The OP25 (15mer) peptide was present in two sub-pools 
(numbers 5 and 13) in the matrix grid (Figure 13 B). In MLPC, the concentration of 
the single 9mer peptide and the matrix sub-pools was 1 µg/ml/peptide. 
Consequently, the total concentration of a matrix sub-pool was 10 µg/ml if it 
contained ten peptides. The CD8+ T cell response was measured by CFSE 
proliferation assay and MHC-tetramer staining.  
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Figure 13: Overlapping peptide sequences and matrix peptide sub-pools covering the JCV-VP1 
sequence: (A) General scheme of overlapping peptide sequences. Each peptide is 15 amino acid 
residues long and overlaps with the next peptide by 11 amino acid residues (bracket 1 and 2). (B) 
Instead of each peptide being tested individually, a total of 19 matrix peptide sub-pools were made 
from 86 JCV-VP1 overlapping peptides. Thus, each individual peptide is present in two different sub-
pools. For example, when peptide sub-pools 5 and 13 are both positive (highlighted), all individual 
peptides present in these two peptide sub-pools could be antigenic, however the intersection of both 
stimulatory sub-pools indicates peptide number 25 (OP25) as antigenic peptide.  
There was a significant positive signal with both the single peptide and the matrix 
sub-pools stimulation. However, the percentage of expanded CD8+ T cells after 
stimulation with the single peptide (Figure 14 A) was marginally higher than those 
stimulated with the matrix sub-pools (Figure 14 B, C). This could be due to 
competition among peptides in the matrix sub-pools for processing and presentation. 
The concentration of the individual peptide in the matrix sub-pools and the single 
9mer peptide was identical, but the molarity was slightly higher for the 9mer peptide. 
The difference in molarity could be another reason for the slightly higher CD8+ T cell 
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response for 9mer peptide. Furthermore, it was seen that irrespective to single 
peptide or matrix sub-pools stimulation, MHC-tetramer positive CD8+ T cells were all 
CFSE low (Figure 14 A, B, C), indicating that all tetramer positive cells have 
undergone proliferation.  
 
Figure 14: Comparison of T cell stimulation by single peptide versus matrix sub-pools: CFSE 
proliferation assay and double-staining with CD8 and MHC-tetramer was performed to visualize the 
JCV-VP1-p100-peptide stimulation. CD8 versus MHC-tetramer analysis dotplots were gated on 
lymphocytes. CFSE versus MHC-tetramer analysis dotplots were gated on CD8+ T cells. MLPC 
assays were performed with (A) JCV-VP1-p100 9mer peptide. (B) JCV-VP1 matrix sub-pool number 
5, which encompassed eight individual 15mer peptides. (C) JCV-VP1 matrix sub-pool number 13, 
which encompassed ten individual 15mer peptides. The OP25, a 15mer peptide was present in both 
sub-pools number 5 and number 13. 
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Overall, we found that a pool of 10 peptides does stimulate a T cell response 
similarly to that elicited by a single immunodominant 9mer peptide. Therefore, it 
constitutes an excellent tool for high throughput screening (HTS) and saves material, 
particularly when the sample cell numbers are limited. 
3.3 Characterization of high-affinity JCV-p100-peptide-specific 
CD8+ T cells  
Out of many peptides derived from a particular foreign antigen, only few peptides 
can induce a measurable T cell response along with a given HLA class I molecule, a 
phenomenon called as immunodominance. In HLA-A2 restricted HDs and patients, 
p100 and p36 are two immunodominant peptides derived from the JCV capsid 
protein VP1 (see Table 1). The crucial factor determining the immunodominance of a 
given epitope is the binding affinity of the peptide to the HLA class I molecules and 
more importantly the affinity of TCR to the peptide-HLA (p-HLA) complex. 
In a HD, who had a reasonable T cell response to the JCV-VP1-p100-peptide, we 
characterized specific T cells using the p100-peptide in a dose-dependent manner 
(10 ng/ml to 10 µg/ml). The p495-503 derived from the CMVpp65 antigen was used 
in parallel as a comparator peptide (Figure 15 A, B).  
Performing a titration of the CMVpp65-derived peptide we observed that T cells were 
responding to peptide concentrations titrated down to 10 ng/ml. Looking closely, a 
strong T cell response was measured at the lowest concentration of 10 ng/ml 
(discussed in 3.2.2.2) (Figure 15 A). Using the JCV-p100-peptide, we observed an 
excellent T cell response at the concentration of 100 ng/ml. Surprisingly 
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concentration as low as 10 ng/ml also stimulated a significantly high T cell response 
(Figure 15 B).  
 
 
Figure 15: Detection of high-affinity T cells: CD8+ T cells were stimulated using four different 
concentrations of peptides starting from left 10 ng/ml, 100 ng/ml, 1 µg/ml and 10 µg/ml. The 
experimental outcome was measured by MHC-tetramer along with CD137 and CD8 staining. (A) 
CMVpp65-peptide-specific MHC-tetramer versus CD8 staining. (B) JCV-VP1-p100-peptide-specific 
MHC-tetramer versus CD8 staining (C) JCV-VP1-p100-peptide-specific MHC-tetramer versus CD137 
staining.    
This high T cell response at a concentration as low as 10 ng/ml suggests that the 
relatively low density of p-HLA complex can efficiently interact with the TCR to elicit a 
significant T cell response, which is characteristic for a high-affinity TCR. In our 
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experiment, it was observed that the relative affinity of T cells specific to JCV-VP1 
and CMVpp65 was very high (Figure 15).  
Additionally, the functional reactivity was measured for the peptide-specific T cells. It 
was demonstrated that all T cells specific to the p100-peptide were also functionally 
active as seen by positive staining for CD137 (Figure 15 C). Overall, our titration 
experiment suggested that the T cells specific to the VP1-p100-peptide expressed 
high-affinity TCR and showed high functional reactivity.  
Long-term culture maintenance of high-affinity T cells specific to JCV-VP1-p100-
peptide   
In the previous section, we observed high and low numbers of T cells at peptide 
concentrations of 100 ng/ml and 10 µg/ml respectively. Here, these T cells were 
maintained with weekly stimulation using irradiated p100-peptide loaded on K562-A2 
cells. After each stimulation T cells were assessed for peptide-specificity by MHC-
tetramer and for functional reactivity by anti-CD137 staining.    
It was observed that p100-peptide-specific T cells stimulated with two different 
concentrations were maintained successfully for a period of almost four weeks. 
Using a peptide concentration of 10 µg/ml, a good frequency of specific T cells was 
observed till the 3rd week. But after the fourth consecutive stimulation there were 
almost no detectable T cells left (Figure 16 A). Overstimulation of T cells with high 
concentrations of peptides might be one possible explanation for the disappearance 
of T cells during long-term culture. On the contrary, when T cells were stimulated 
with peptides at a 100 fold dilution (100 ng/ml), significant T cell responses were 
observed which were maintained throughout the period of culture (Figure 16 B).  
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Figure 16: Long-term culture of JCV-VP1-p100-peptide-specific CD8+ T cells: CD8+ T cells were 
maintained for over four weeks with two different concentrations of JCV-VP1-p100-peptide. Cells 
were stained for JCV-VP1-p100-peptide-specific MHC-tetramer along with CD137 and CD8 
antibodies. CD8+ T cells were stimulated weekly with irradiated K562-A2 cells pulsed with (A) 10 
µg/ml peptide (B) 100 ng/ml peptide.   
Moreover, we observed that all T cells were functionally reactive as measured by 
staining for CD137. However, using peptide at a concentration of 10 µg/ml, some 
non-specific T cells (MHC-tetramer negative) were also detected to be CD137 
positive (Figure 16 A). This was not the case when 100 ng/ml peptide was used 
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since all CD137 positive cells were only double-positive for peptide-specific T cells 
(Figure 16 B).    
Overall, we were able to generate high-affinity JCV-specific CD8+ T cells that were 
functionally active and could be maintained in an in vitro culture for at least four 
weeks.   
3.4 Cross-reactivity of CD8+ T cells specific to JCV and BKV 
Between JCV and BKV, almost 70% of the genome and 87% of the VP1-protein 
sequence is homologous (Figure 17). Thus it is not very surprising that T cells are 
cross-reactive for these two virus-derived peptide epitopes.  
 
Figure 17: Alignment of JCV-VP1 versus BKV-VP1 using the data base protein BLAST 
(blast.ncbi.nlm.nih.gov): Query and subject represents JCV-VP1 and BKV-VP1 amino acid 
sequences. Highlighted are the homologous amino acid sequences for JCV-VP1-p100 (ILMWEAVTL) 
and BKV-VP1-p108 (LLMWEAVTV) peptides respectively.      
In our study, we selected HLA-A2 restricted immunodominant peptides derived from 
the capsid protein VP1 of JCV and BKV (JCV-VP1-p100: ILMWEAVTL and BKV-
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VP1-p108: LLMWEAVTV). These 9mer peptides were homologous for both viruses 
except at the first and the last position amino acid residues (Figure 17). After MLPC, 
each peptide-stimulated CD8+ T cell responses were measured by both JCV and 
BKV peptide-specific MHC-tetramers. Peptide-stimulated T cells were measured 
equally when both JCV and BKV-specific MHC-tetramers were used in a criss-cross 
manner. This indicated that there was high TCR cross-reactivity between T cells 
specific for both JCV and BKV (Figure 18). We also observed functional cross-
reactivity among these T cells. 
 
Figure 18: TCR cross-reactivity between T cells specific for JCV and BKV peptides: CD8+ T 
cells were stimulated with JCV and BKV immunodominant peptides respectively. After a week of 
culture, cells were double-stained for CD8+ T cells and MHC-tetramers. Complete medium (no 
peptide) stimulated CD8+ T cells were used as negative control.   
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3.5 HLA-typing of HDs 
Allele-specific antibodies were initially used to type HDs for HLA-A2 and HLA-B7. In 
this context, K562 cells transfected with HLA-A2 and HLA-B7 were used as positive 
controls in flow cytometry. Additionally, K562 cells transfected with HLA-A1, HLA-B7 
and HLA-B8 were also used as internal controls to exclude cross-reactivity. We 
observed that HLA-A2 allele-specific antibody (BB7.2) staining was distinct and clear 
and did not show any cross-reactivity to other HLA-alleles (HLA-A1, HLA-B7, HLA-
B8) (Figure 19 A). However, using the HLA-B7 allele-specific antibody, we observed 
that staining was not of high intensity and it also showed cross-reactivity to the K562-
A1 transfectants (Figure 19 B). To solve this problem SSP-PCR protocol was 
standardized and sequence specific primers were selected for HLA-A2 (Bunce 2003) 
and HLA-B7 (Hollsberg 2002). Primers were analyzed using primer-BLAST and 
product length was determined for HLA-A2 (494bp) and HLA-B7 primers set (119bp). 
These primers were then tested for the optimum annealing temperature using the 
gradient PCR method. According to Tm of primer sets, the temperature for gradient 
PCR was set. At 64.80C using DNA obtained from K562-B7 cells as a positive 
control and no DNA as a negative control, we observed a clear band of 119bp by gel 
electrophoresis (Figure 20 A). Using this temperature as annealing temperature, a 
PCR protocol was established and HDs were typed for the HLA-B7 allele. We 
detected a clear band of 119bp with DNA from K562-B7 cells with no cross-reactivity 
across HLA class I when SSP-PCR was used (Figure 20 B). Likewise, protocol for 
HLA-A2 was also established using SSP-PCR.   
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Figure 19: HLA-typing by flow cytometry: Histograms showing overlays of isotype control and 
allele-specific fluorescent antibody staining. K562 transfectants for HLA-A1, HLA-A2, HLA-B7 and 
HLA-B8 were stained with (A) isotype control and HLA-A2-specific antibody (BB7.2), (B) isotype 
control and HLA-B7-specific antibody respectively.     
 
Figure 20: Gel electrophoresis of SSP-PCR products: (A) Gradient PCR using K562-B7 DNA and 
no DNA as positive and negative control respectively. The gradient temperature was set according to 
the calculation of Tm of the primer set. (B) PCR at 64.80C using all the transfected K562 cell lines and 
an HLA-B7 positive healthy donor.   
In summary, both methods of antibody mediated flow cytometry and PCR were 
employed for HLA-typing of HDs. However, due to unwanted cross-reactivity in flow 
cytometric approach we used latter approach for specific HLA-typing, especially for 
HLA-B7 allele. Using both approaches, it was observed that out of total donors 
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tested 50% were HLA-A2 positive, 30% were HLA-B7 positive and 13% were 
positive for both HLA-A2 and HLA-B7 allele. 
3.6 Pre-screening of JCV-VP1-specific T cells in HDs  
At present, the measurement of anti-VLP antibodies and JCV-DNA in the urine, 
constitute the two methods used to determine a present or past JCV infection or 
reactivation. Combining these two methods almost 70-90% of the human population 
was shown to be seropositive.  However, it is not clear whether a JCV seropositive 
individual also constitute a JCV-specific positive T cell response which is marked by 
circulating T cells (Jelcic, Aly et al. 2013). Here we tried to screen HDs for positive T 
cell response prior to detailed analysis. 
HDs pre-screening was performed after one week of MLPC. Pre-screening of non-
HLA-A2 positive donors was performed by using a JCV-VP1-peptide pool in CFSE 
proliferation and IFN-γ ELISPOT assays. To screen HLA-A2 positive HDs, two 
immunodominant peptides derived from JCV-VP1 (p36 and p100) and corresponding 
MHC-tetramers were also used. We observed that using different experimental 
technique every two out of ten HDs were screened positive for JCV-VP1-specific T 
cells.  
When comparing different read-outs for pre-screening, we observed that even if 
CFSE proliferation assay was sensitive and convenient to use, results were not 
always equivalent to IFN-γ ELISPOT assay (Figure 21 A, B). To compare in MLPC, 
p100-specific T cell responses were measured in two HLA-A2 positive HDs using 
proliferation and ELISPOT assay. The numbers of IFN-γ secreting T cells were 
comparable in both donors. However, a difference was found between populations 
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which undergone proliferation (Figure 21 A, B). Similar results were also obtained 
using p36-peptide (data not shown).  
 
Figure 21: Pre-screening of HDs, based on proliferation and IFN-γ secretion: MLPC was 
performed using p100-peptide. Here, T cells were also labelled with CFSE. After 6 days of culture, 
one half of T cells were stained with anti-CD8 antibodies and measured for CFSE labelling in flow 
cytometry. Another half was restimulated for IFN-γ secretion in the ELISPOT assay. (A) HD1 has 
undergone more rounds of proliferation (MFI: 815). (B) HD2 has undergone less rounds of 
proliferation compared to HD 1 (MFI: 1564). MFI: mean fluorescence intensity.  
Overall, we could analyze HDs for JCV-specific T cells irrespective of HLA restriction 
based on the peptide-specific TCR, proliferation and IFN-γ secretion properties. Also, 
we found that for pre-screening purpose, information about proliferation by CFSE 
alone was insufficient so this method was always combined with either IFN-γ 
secretion or MHC-tetramers.      
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3.7 Processing of JCV-VP1-VLP 
In order to find out whether the responding antigenic peptides were naturally 
processed, we used JCV-VLP as antigens for stimulation. JCV-VLP were a generous 
gift from Prof. Alma Gedvilaite (Vilnius University). VLP is a multimeric protein made 
of refolded recombinant VP1 and has a morphologic and structural similarity to the 
natural JCV capsid (Chang, Fung et al. 1997; Zielonka, Gedvilaite et al. 2006). 
 
Figure 22: Analysis of JCV-VLP processing: (A) MLPC was performed using the VP1-peptide pool 
as stimulus. (B) MLPC was performed using JCV-VLP as stimulus. First, second and third bar in both 
graphs show restimulation performed with complete medium (no peptide), VP1-peptide pool and JCV-
VLP.   
We wondered whether JCV-VLP-stimulated T cells could recognize JCV-VP1-
peptide pool and vice-versa. To this end to assess this problem, CD8+ T cells were 
stimulated with JCV-VP1-peptide pool (Figure 22 A) and VLP (Figure 22 B) in 
parallel. Restimulation was performed using both the VP1-peptide pool and VP1-
VLP. Complete medium served as negative control. We observed that VP1-peptide 
pool stimulated T cells showed high T cell responses after restimulation with JCV-
VLP (Figure 22 A). Similar T cell responses were observed with VLP-stimulated cells 
when restimulation was effective by the VP1-peptide pool (Figure 22 B). In both 
settings, a positive signal in the ELISPOT assay demonstrated that VP1-protein 
antigen was processed and the peptides resulting from the proteasomal cleavage 
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process were successfully presented via HLA class I molecules to CD8+ T cells.  
Moreover, equally high T cell responses were observed after stimulation and 
restimulation with the same antigen (Figure 22 A, B).   
 
Figure 23: Analysis of VLP processing using the OP25 peptide: (A) MLPC was performed using 
complete medium (no peptide) versus the OP25 peptide as a stimulus. (B) In MLPC JCV-VLP served 
as stimulus. The first and the second bar in both graphs show restimulation performed with complete 
medium and the OP25 peptide.   
Furthermore, using an individual 15mer peptide designated OP25 which 
encompassed JCV-TCE p100, we confirmed the natural processing of JCV-VLP. In 
the experiment shown in Figure 23, two MLPCs were performed in parallel, the first 
MLPC was stimulated by the OP25 peptide and the second MLPC by JCV-VLP. Both 
cultures were thereafter restimulated with OP25 peptide in the ELISPOT assays.  
We observed positive T cell responses to OP25 when the peptide was used for both 
stimulation and restimulation (Figure 23 A). Equally good T cell responses were 
observed when VLP-stimulated T cells were restimulated with OP25 peptide (Figure 
23 B). Responses to the individual peptide by JCV-VLP-stimulated T cells confirmed 
that the VLP is naturally processed and VLP-derived peptides are presented on HLA 
class I molecules.     
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Overall, we observed that JCV-VLP are processed and presented efficiently by 
APCs in MLPC. Furthermore, processing was confirmed by using immunodominant 
JCV-TCEs.  
3.8 Assessment of novel JCV-VP1 CD8+ T cell epitopes (TCEs) 
3.8.1 Novel T cell epitopes (TCEs) in HDs 
In order to map T cell antigens, a comprehensive approach using 19 JCV-VP1-
peptide sub-pools were employed in a matrix setup (discussed in 3.2.2.3, Figure 13). 
All HDs were first HLA-typed by flow cytometry and SSP-PCR methods (discussed in 
3.5). Donors, who were positive for HLA-A2 and HLA-B7 were selected and 
analyzed for T cell reactivity to the JCV-VP1-peptide pool. Samples from HDs 
showing positive immune responses were then used for further identification of 
potential TCEs. A systematic scheme for identification of TCEs to JCV-VP1 is 
displayed in Figure 24. The first step was to identify dominant T cell specificities 
using the peptide matrix pool approach (Figure 24 A). Here, the stimulation (at day 0) 
was initiated by JCV-VLP. This was a very important step, as it confirmed that the 
stimulating antigenic peptides were not artificial but naturally processed. After 
identification of a particular T cell specificity, restriction analysis was performed using 
HLA-transfectants loaded with individual 15mer peptides (Figure 24 B). For this 
purpose, T2 cells and K562 cells transfected with HLA-A2 or HLA-B7 alleles were 
used as APCs. To further characterize the minimal epitope, 9mer peptides were 
predicted by the use of the SYFPEITHI software (http://www.syfpeithi.de/), 
synthesized and then tested individually (Figure 24 C).  
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By IFN-γ ELISPOT assays, strength of T cell responses was estimated using 
stimulation index (S.I) which was calculated for each positive signal after dividing the 
number of dots in the experimental wells in the 96-well plate with the negative control 
wells. Based on this index, T cell responses were classified as weak (between 2 and 
3), moderate (between 3 and 4) or strong (≥4).  
 
Figure 24: Systematic scheme of T cell epitope mapping: (A) Identification of T cell specificities 
using the peptide matrix pool approach. (B) Determination of the restriction molecule using selected 
individual 15mers in combination with HLA-transfectants. (C) Determination of the fine epitope 
specificities using predicted 9mer peptides.  
The first step, i.e. the identification of T cell specificities using the peptide matrix pool 
is a very crucial one. A representative experiment employing peptide matrix pool 
stimulation is depicted in Figure 25. In this representative example, JCV-VLP-
stimulated CD8+ T cells were restimulated with 19 peptide matrix sub-pools in an 
ELISPOT plate with each restimulation in duplicate. Complete medium and SEB 
stimulation served as negative and positive controls, respectively. Two positive 
responding peptide sub-pools (sub-pools 10 and 11) were identified on the basis of 
number of IFN-γ secreting cells (red ellipses) (Figure 25 A, B). In a further step, the 
common peptide present in both peptide sub-pools was selected with the help of 
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matrix grid (Figure 25 C). This 15mer peptide (in this experiment: OP10) was used in 
subsequent experiments to analyze the T cell reactivity.     
 
Figure 25: T cell epitope screening using matrix peptide sub-pools: (A) ELISPOT wells showing 
negative and positive controls as well as wells stimulated by nineteen different peptide sub-pools in 
duplicate. Experimental wells stimulated with peptide sub-pools 10 and 11 were marked as positive 
results. (B) Histogram with bars representing IFN-γ secreting cells per 25,000 cells. Based on the T 
cell responses, two matrix peptide sub-pools were selected (red ellipses) and (C) the corresponding 
individual 15mer peptide common to both sub-pools was identified (OP10) in the matrix grid. 
Retrieval of previously known JCV-VP1 T cell epitopes 
Using the matrix approach, we were able to confirm two previously known HLA-A2 
restricted JCV-VP1 epitopes p36 and p100. Using the two 15mer peptides OP9 and 
OP25 containing these epitopes, we found T cell reactivity in more than 4 out of 12 
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donors (Table 3). Additionally, p36 and p100-peptides were used in all 22 HLA-A2 
positive donors tested and we found that 31% donors were positive for p36 and 41% 
donors were positive for p100-peptides (Table 5).   
Identification of novel T cell specificities 
In addition to reactivity to p36 and p100-peptides, we found several other 
specificities in HLA-A2 positive donors (Table 3). Some of the T cell responses to a 
particular antigenic peptide were shared by more than three HDs (≥25% HDs), for 
e.g. the peptides OP9, OP25, OP28, OP29, OP72 and OP78. In four different 
donors, stimulation by the two 15mers OP72 and OP78 resulted in positive signals. 
Especially donor#4318 showed a strong T cell response to the OP72 peptide in three 
independent experiments. Experiments towards the characterization of 9mers 
predicted from OP72 and OP78 are ongoing. The peptide OP29 was another 15mer 
peptide with strong signals in 33% of the donors we tested. Using the SYFPEITHI 
software, the 9mer peptide named p113 was predicted. The peptide was synthesized 
and used in experiments with twelve HLA-A2 positive donors. We observed that 3 
out 12 donors tested were positive for T cell responses to peptide p113 including the 
HD#0132 who showed an exceptionally strong T cell response.  
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Table 3: Antigenic peptides tested in HLA-A2 positive healthy donors (HDs). TCE of 15mers OP9 
and OP25 peptides was described (see Table 1). All other antigenic peptides described here are 
novel. The restriction molecules were predicted using SYFPEITHI software (http://www.syfpeithi.de/). 
ID represents the last three to four digits from the blood bank code for the HDs.  
JCV-VP1-peptides ID In silico predicted T cell epitope Experimental T cell reactivity 
0196 Weak 
6551 Moderate 
2004 Moderate 
4195 Moderate 
GVDSITEVECFLTPE (OP9)  
4318 
S I T E V E C F L 
Moderate 
MLPCYSVARIPLPNL (OP20) 0196 V A R I P L P N L Moderate 
0196 Moderate 
4895 Moderate 
0132 Moderate 
CGNILMWEAVTLKTE (OP25) 
2004 
I L M W E A V T L 
Moderate 
4895 Moderate 
2004 Weak 
KTEVIGVTSLMNVHS (OP28) 
5728 
T E V I G V T S L 
Moderate 
0196 Strong  
4895 Moderate 
2004 Weak 
IGVTSLMNVHSNGQA (OP29) 
5728 
I G V T S L M N V 
Moderate 
PVECWVPDPTRNENT (OP50) 0196 W V P D P T R N E Moderate 
PTRNENTRYFGTLTG (OP52) 0196 E N T R Y F G T L Moderate 
VDVCGMFTNRSGSQQ (OP65) 0196 G M F T N R S G S Weak 
4318 Strong 
2004 Moderate 
0065 Weak 
KRRVKNPYPISFLLT (OP72) 
5728 
 K N P Y P I S F L 
Moderate 
KNPYPISFLLTDLIN (OP73) 4318 P I S F L L T D L Moderate 
0132 Moderate 
5728 Moderate 
0014 Weak 
VDGQPMYGMDAQVEE (OP78) 
0196 
P M Y G M D A Q V 
Weak 
PMYGMDAQVEEVRVF (OP79) 0132 G M D A Q V E E V Moderate 
GTEELPGDPDMMRYV (OP83) 0196 E L P G D P D M M Moderate 
4895 Moderate  
132 Strong 
IGVTSLMNV (p113) 
0196 
I G V T S L M N V 
Weak 
0992 Strong 
4090 Strong  
0132 Moderate  
0207 Strong 
2564 Strong 
2004 Moderate  
4895 Strong 
4195 Moderate 
ILMEWEAVTL (p100) 
4318 
I L M W E A V T L 
Moderate 
0196 Strong 
4129 Weak 
2564 Moderate 
2004 Weak 
4195 Strong 
4318 Moderate 
SITEVECFL (p36) 
4895 
S I T E V E C F L 
Weak 
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In HLA-B7 positive donors, we observed moderately positive T cell responses to 
15mer peptides at a frequency of one out of ten HDs (Table 4). In an attempt to 
characterize TCEs in one donor#4196, who was positive to the 15mer peptide OP76 
(Table 4), the predicted 9mer was synthesized and tested. However, corresponding 
9mer peptide (p306) stimulus gave no T cell responses (data not shown). In another 
experiment, donor#4278 showed exceptionally strong secretion of IFN-γ when T cells 
were stimulated with 9mer peptide p244 (Table 4). These results were reproducible 
in independent experiments and none of the other nine donors showed T cell 
responses to this peptide.  
Table 4: Antigenic peptides tested in ten HLA-B7 positive healthy donors (HDs). All peptides 
described here are novel. The restriction molecules were predicted using SYFPEITHI software 
(http://www.syfpeithi.de/). ID represents the last three to four digits from the blood bank code for the 
HDs.  
JCV-VP1-peptides ID In silico predicted T cell 
epitope 
Experimental T cell reactivity 
TPEMGDPDEHLRGFS (OP12) 1608 D P D E H L R G F Weak 
GDPDEHLRGFSKSIS (OP13) 4106 D P D E H L R G F Strong 
ESDSPNRDMLPCYSV (OP18) 4169 S D S P N R D M L Moderate 
4106 Moderate PNLNEDLTCGNILMW (OP23) 
4196 
E D L T C G N I L 
Weak 
HDNGAGKPVQGTSFH (OP33) 4106 K P V Q G T S F H Weak 
VLFNYRTKYPDGTIF (OP40) 4106 R T K Y P D G T I Moderate 
4106 Weak ENTRYFGTLTGGENV (OP53) 
4196 
E N T R Y F G T L 
Moderate 
PVLHITNTATTVLLD (OP57) 4106 I T N T A T T V L Moderate 
PLCKGDNLYLSAVDV (OP62) 4169 L C K G D N L Y L Moderate 
KRRVKNPYPISFLLT (OP72) 4169 N P Y P I S F L L Moderate 
LINRRTPRVDGQPMY (OP76) 4196 T P R V D G Q P M Moderate 
RVFEGTEELPGDPDM (OP82) 1608 R V F E G T E E L Moderate 
GPLCKGDNL (p244) 4278 G P L C K G D N L Strong 
1608 Moderate NPYPISFLL (p290) 
4106 
N P Y P I S F L L 
Weak 
1608 Moderate 
4106 Weak 
VARIPLPNL (p83) 
4195 
V A R I P L P N L 
Moderate 
 
In summary, we observed that among all HLA-B7 restricted T cell specificities given 
in Table 4, two out of ten donors showed T cell responses to the peptides OP23, 
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OP53 and p290, whereas three out of ten donors tested were positive for the 9mer 
peptide p83. The p83-peptide was also shown to be immunogenic in one patient 
sample (discussed in 3.8.2).  
Based on the frequency and strength of T cell responses in HDs, some of the 
candidate TCEs including p36 and p100 were summarized in Table 5. It was 
observed that the frequency of positive donors for all candidate TCEs were in the 
range of 25% to 41% with the top score for p100-peptide. To estimate the relative 
strength of T cell stimulation by each antigen peptide in a responding donor, we 
calculated the magnitude (index) of T cell responses. For example, a strong, 
moderate and weak T cell response to a particular antigenic peptide in a single 
donor was given a magnitude (index) of 1, 0.66 and 0.33 respectively. Based on this 
calculation, it was observed that in a positively responding HD, T cell responses to 
p100-peptide were very high while T cell responses to OP78 peptide were of lowest 
magnitude.   
Table 5: Donor frequencies specific to potential TCEs. 
JCV-VP1-peptides Total donors tested Positive 
donors 
Magnitude (index) of T cell response (maximum 1) 
p83 10 3 (30%) 0.55 
OP29 12 4 (33%) 0.66 
OP72 12 4 (33%) 0.58 
OP78 12 4 (33%) 0.50 
p113 12 3 (25%) 0.66 
p100 22 9 (41%) 0.86 
p36 22 7 (31%) 0.59 
 
In summary, we could observe several novel candidate HLA class I-TCEs in HLA-A2 
and HLA-B7 positive HDs using our approach. Additionally, previously described 
HLA-A2 restricted immunodominant peptides were confirmed. Using JCV-VLP as 
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primary stimulus, we demonstrated that all newly defined TCEs were naturally 
processed.  
3.8.2 Novel T cell epitopes (TCEs) in a patient  
In addition to HDs, we had the opportunity to analyze a patient for polyoma-reactive 
CD8+ T cells. The HLA class I and class II typing is shown in Table 6. 
Table 6: HLA-typing of patient blood sample. 
HLA-A HLA-B HLA-C DRB1* DQB1* DQA1* 
3 29 7 44 W*07 W*16 0101 0701 05 02 0101 0201 
 
This patient had a history of a severe HC. Due to his previous exposure to BKV, we 
decided to analyze the T cell response to BKV-VLP. In parallel, cross-reactivity to 
JCV was also measured using stimulation with JCV-VLP, the JCV-VP1-peptide pool 
and a pool of HLA-B7-binding peptides. HLA-B7-binding peptides were considered 
for two reasons. Firstly, a more comprehensive approach (e.g. individual peptides of 
VP1-protein) was not possible due to limited availability of patient sample. Secondly, 
our lab has a long-standing interest in the HLA-B7 molecule and T cell specificities 
restricted to HLA-B7 (clinical study: CMVpp65 vaccination in patients after stem cell 
transplantation).  
To this end, the amino acid sequence of the JCV-VP1-protein was screened and six 
nonamer HLA-B7-binding peptides were predicted on the basis of prediction scores 
using two programs SYFPEITHI (http://www.syfpeithi.de/) (score of more than 18) 
and BIMAS (http://www-bimas.cit.nih.gov/molbio/hla_bind/) (score of more than 180). 
In MLPCs, CD8+ T cells were stimulated using DCs loaded with JCV-VLP, the JCV-
VP1-peptide pool and a pool of HLA-B7-binding peptides. In IFN-γ secretion assays 
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we observed high T cell responses to both BKV-and JCV-VLP (Figure 26 A, B). 
Moreover, we observed equally high T cell responses to both the VP1-peptide pool 
and the pool of HLA-B7-binding peptides derived from JCV (Figure 26 A, B). A 
positive response to the pool of HLA-B7-binding peptides suggests the presence of 
possible T cell determinants in this pool.   
 
Figure 26: T cell responses to JCV and BKV in a HLA-B7 positive patient: IFN-γ ELISPOT 
assays were performed using autologous DCs loaded with complete medium, BKV-VLP, JCV-VLP, 
the JCV-VP1-peptide pool and a B7-peptide pool. IFN-γ secretion by T cells as original data in 
ELISPOT plate wells as well as histogram with bars indicating the respective S.I. (S.I.: for further 
details see page 67)   
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To identify further which one of the HLA-B7-binding peptides induced a positive 
CD8+ T cell response, MLPCs were performed using individual peptides. First, CD8+ 
T cells were stimulated using DCs loaded with JCV-VLP. Then, CD8+ T cells were 
restimulated in ELISPOT assays using JCV-VLP, the pool of HLA-B7-binding 
peptides and all the HLA-B7-binding peptides individually. In the ELISPOT assays, 
complete medium and SEB served as negative and positive controls respectively. 
We observed that there were significantly high T cell responses to JCV-VLP. 
Additionally, strong T cell responses were measured to the individual peptide p83 
while moderate T cell responses were observed to p306-peptide (Figure 27 A, B). 
Other peptides showed rather low or no IFN-γ secretion. Since the first stimulation 
was effective through JCV-VLP loaded DCs, it was evident that all responding 
peptides were naturally processed.  
We also observed T cell responses to the pool of HLA-B7-binding peptides. 
However, the T cell response was low when compared to the individual peptides and 
VLP (Figure 27 A, B). The lower response might be due to peptide competition (six 
peptides in a pool) for binding to the presenting HLA molecules.  
In conclusion, in a patient with a previous history of HC we observed high T cell 
responses to both BKV-and JCV-VLP which indicates the possibility of cross-
reactivity among BKV-and JCV-specific T cells. Furthermore, we found T cell 
specificities to the two predicted HLA-B7-binding peptides p83 and p306. Both 
peptides were demonstrated to be naturally processed.  
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Figure 27: TCE mapping in a patient: IFN-γ ELISPOT assays were performed using autologous 
DCs loaded with complete medium, JCV-VLP, the pool of HLA-B7-binding peptides and six individual 
HLA-B7-binding peptides. IFN-γ secretion by T cells as original data in ELISPOT plate wells as well as 
histogram with bars indicating the respective S.I. (S.I.: for further details see page 67).  
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4 DISCUSSION 
Frequencies of JCV-specific T cells  
Ex vivo stimulation using an array of peptides constitutes a widely used method to 
detect precursor frequencies (Sun, Burton et al. 2000; Pittet, Zippelius et al. 2001; 
Anthony and Lehmann 2003; Speiser, Pittet et al. 2004; Guerreiro, Na et al. 2010; Li 
Pira, Ivaldi et al. 2010). To assess the precursor frequency specific to JCV, we 
performed ex vivo IFN-γ secretion assays using VP1-peptide pool in eight HDs. 
Using 100,000 PBMCs as effector cells, stimulation was performed for almost 24 hrs 
but no T cell reactivity to JCV-VP1-peptide pool was observed. To assess the 
precursor T cell number one week expansion step was performed and relative T cell 
frequencies were measured (Table 2). Here, we found that after in vitro stimulation, 
frequencies towards JCV were lower when compared to other viruses like CMV and 
the influenza virus (van Aalderen, Remmerswaal et al. 2013) (Table 2). One possible 
explanation for this low frequency of JCV-specific T cells is the replication pattern of 
persistent viruses in an immunocompetent individual. The primary infection of JCV 
occurs during childhood and once the viruses are cleared, it remains latent in sites 
like the urogenital tract or CNS. In these anatomical compartments, viruses replicate 
occasionally (Polo, Perez et al. 2004). Also, JCV normally is not found in blood 
(viremia) (Koralnik, Boden et al. 1999). Taken together these factors might be the 
reason for the generation of a rather low number of memory T cells.  Nevertheless, 
this low number of memory T cells is potent enough to control JCV-reactivation in the 
immunocompetent host.  
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Optimization of the T cell expansion protocol 
Due to very low precursor frequency, ex vivo monitoring of JCV-specific T cells is 
very difficult. Therefore, an in vitro expansion protocol was necessary. Optimization 
of such a protocol was crucial, especially for the successful stimulation of low-affinity 
T cells. Here, we compared different protocols varying in the type of APCs like 
monocytes, PBMCs, and depleted fraction of CD8+ T (CD8-) cells. Autologous 
PBMCs as APCs has been already reported earlier (Fu, Freed et al. 2001; Binggeli, 
Egli et al. 2007; Ginevri, Azzi et al. 2007; Marzocchetti, Lima et al. 2009). Using 
immunodominant peptides-derived from two different viruses, we observed an 
almost 5-to 8.5-fold increase in the expansion of peptide-specific CD8+ T cells when 
CD8- was used as APCs at a four times higher ratio (Figure 8 and Chapter 3.2.1). A 
CD8+ to CD8- cell ratio of 1:4 was previously optimized in our lab. Here, CD8- cells 
not only served as autologous feeder cells but also as APCs. It has been observed 
that in the absence of feeder cells, CD8+ T cells were unable to expand (Al-Shanti 
and Aldahoudi 2007). Moreover, CD8- cells were irradiated which ensured that this 
fraction would not proliferate and only CD8+ T cells would contribute in the overall 
expansion. The importance of irradiated autologous feeder cells has been discussed 
in one study where it is proposed that irradiating <50% of PBMCs contributes in high 
proliferation of non-irradiated PBMCs (Jackson, Dimopoulos et al. 2004). 
Additionally, to support the T cell culture, two recombinant cytokines IL-2 and IL-7 
were used in our protocol. The role of IL-2 in T cell proliferation has been already 
demonstrated (Friedmann, Migone et al. 1996; Ahmed, Grimes et al. 1997). The 
selection of IL-7 was based on the fact that all memory T cells express IL-7R-α on 
their surface (He, Mahmood et al. 2003; de Bree, Heidema et al. 2005).  
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ELISPOT assays 
To identify in vitro stimulated T cells even at low frequency we used ELISPOT 
assays as a sensitive read-out system (McCutcheon, Wehner et al. 1997). For the 
optimization we used different types of APCs at different ratios (Chapter 3.2.2.1). 
Cell lines like K562 and T2 were confirmed to be as good as autologous PBMCs to 
restimulate CD8+ T cells in ELISPOT plates (Chapter 3.2.2.1). SEB, a super-antigen 
which has been shown to stimulate T cells non-specifically, served as a positive 
control (Boshell, McLeod et al. 1996; McLeod, Walker et al. 1998). SEB was 
preferred over PHA because in our hands it gave more reproducible results than 
PHA: SEB was used to stimulate T cells in the presence of APCs as it has been 
reported that in the absence of co-stimulation, SEB causes T cells to undergo 
apoptosis instead of proliferation (Boshell, McLeod et al. 1996; McLeod, Walker et al. 
1998).  
Peptide length 
The effect of peptide length on the initiation of T cell responses is still under debate 
(Zwaveling, Ferreira Mota et al. 2002; Sercarz and Maverakis 2003; Bijker, van den 
Eeden et al. 2008). In order to analyze whether HLA-transfectants could efficiently 
process longer peptides (15mer) and stimulate T cell responses, we used 9mer and 
15mer peptides derived from two different viral antigens. It was observed that 15mer 
peptides can be efficiently processed and presented by both PBMCs and cell lines 
(Chapter 3.2.2.2 and 3.2.2.3). This information was very crucial for establishing 
strategy for restriction analysis of antigenic peptides using HLA-transfectants (Figure 
24).  
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Using titrations of 9mer and 15mer peptides, we observed that 9mer peptides are 
superior in initiating T cell responses. At low concentrations, the dose-response 
curve of 15mer peptides was still in a linear phase while it was already in plateau 
with the same concentration of 9mer peptide (Figure 12, 16) (Kiecker, Streitz et al. 
2004). This indicates that for the initiation of T cell responses, higher concentrations 
of 15mer peptides is required when compared to 9mer peptides (Figure 12).  
Characterization of JCV-VP1-specific T cells 
In order to characterize T cells specific for JCV-peptides, we selected HDs screened 
positive for nonamer JCV-VP1-p100 and CMVpp65-peptide. Using four different 
concentrations of JCV-VP1 and CMVpp65-peptides (10 ng/ml, 100 ng/ml, 1 µg/ml 
and 10 µg/ml), the relative affinity or avidity of peptide-specific T cells were 
determined. MHC-tetramers were used to measure the peptide-specific T cells. It 
has been reported that the affinity of TCRs can be estimated using MHC-tetramer 
(Yee, Savage et al. 1999; Holmberg, Mariathasan et al. 2003; Naeher, Daniels et al. 
2007). In our study the relative affinity was analyzed by titration of the peptide, and 
MHC-tetramers were used as read-out to detect responding peptide-specific CD8+ T 
cells.  
Significant T cell responses were observed to all concentrations of JCV-VP1-p100-
peptide down to 10 ng/ml. At the lowest (10 ng/ml) peptide concentration, we 
measured strong T cell responses, which indicated that these T cells had high-
affinity TCRs (Figure 15 B). Similar responses were also observed for CMVpp65-
peptide-specific T cells which are known for their high-affinity TCRs (Kiecker, Streitz 
et al. 2004; Trautmann, Rimbert et al. 2005) (Figure 15 A). Moreover, using the 
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p100-peptide at concentrations higher than 100 ng/ml, we observed no rise in T cell 
frequency with serially increased concentrations of the peptide (Figure 15 B). Similar 
results were observed using the CMVpp65-peptide (Figure 15 A). Using the p36-
peptide, the second immunodominant HLA-A2 restricted peptide derived from JCV-
VP1, we similarly observed high-affinity T cells at lower (10 ng/ml) concentration. A 
reasonable explanation for this phenomenon is the fact that T cell responses at this 
low concentration (10 ng/ml) were already in the plateau of the dose-response curve. 
Therefore increasing the peptide concentration did not augment the T cell response. 
It is evident that a low amount of antigen can elicit a T cell response. In other words, 
high-affinity T cells can bind and respond to a low amount of peptide-HLA complex 
presented on the APCs (p-HLA density). 
Other than density of the p-HLA complex, optimal duration of the interaction of TCR 
and p-HLA complex (Obst, van Santen et al. 2005; Prlic, Hernandez-Hoyos et al. 
2006; Celli, Lemaitre et al. 2007; Celli, Garcia et al. 2008; Henrickson, Mempel et al. 
2008) and repeated encounters with the  p-HLA complex (Celli, Garcia et al. 2005; 
Garcia, Pradelli et al. 2007) also have a profound impact on the proliferation and 
function of T cells. Collectively, this indicates that a low amount of peptides along 
with HLA class I sets an activation threshold of p-HLA density during the primary 
infection in HDs which favours the stimulation of high-affinity T cells (Viola and 
Lanzavecchia 1996). Below and above this activation threshold window, T cells will 
not get activated or become anergic. In our study, we did not measure the activation 
window and density of p-HLA on the APCs. However, we observed high T cell 
responses at 100 ng/ml concentration of p100-peptide. This indicates that 
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presumably at this concentration of peptide an optimum TCR-p-HLA interaction had 
occurred.  
Measuring the specificities of TCR using MHC-tetramers does not give any 
information on the functional avidity of T cells which is characterized by inflammatory 
(cytokine release), antiviral (cytotoxicity) and proliferative responses. In order to 
characterize the functional reactivity of high affinity T cells, we measured CD137 on 
the surface of T cells as suggested by other reports (Pollok, Kim et al. 1993; Pollok, 
Kim et al. 1995; Wehler, Karg et al. 2008). We observed that high-affinity 
polyomavirus-specific T cells were all functionally active as well (Figure 15 C). In this 
context, one report showed that high-affinity CD8+ T cells stimulated with a low dose 
of viral-peptide antigen were functionally more active than those T cells stimulated 
with high dose (Alexander-Miller, Leggatt et al. 1996). Similarly, in a tumor 
(melanoma) model, it was reported that a low dose of antigen stimulates high-affinity 
functional T cells (Bullock, Mullins et al. 2003; Lovgren, Baumgaertner et al. 2012).  
Furthermore, to assess the longevity of high-affinity T cells in in vitro cultures, we 
compared p100-specific T cells stimulated with high concentration of the peptide (10 
µg/ml) and low concentration of the peptide (100 ng/ml) for four weeks (Figure 16 A, 
B). We observed that repeated stimulation by low concentrations of the peptide 
dramatically increased the number of MHC-tetramer positive T cells (Figure 16 B). 
On the other hand, repeated stimulation by high concentration of the peptide (10 
µg/ml) did not have any adverse effect till the third week of stimulation. However 
after the 4th stimulation almost no peptide-specific T cells were detected (Figure 16 
A). These results were in-line with a study, where T cells stimulated with higher 
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concentrations of peptides in the in vitro culture underwent activation induced cell 
death (AICD) (Schamel, Arechaga et al. 2005).  
Novel TCEs derived for JCV-VP1  
In the present study, we explored CD8+ T cell responses with the objective to identify 
new TCEs specific for JCV toward future vaccination approaches. For this purpose, 
we focused on two alleles, HLA-A2 and HLA-B7 expressed in 50% and in 25% of the 
Caucasian population, respectively. HLA-A2 and HLA-B7 positive HDs were first 
screened for the presence of T cell responses to JCV infection. Two routinely 
practiced methods for the measurement of JCV infection in individuals are anti-VLP 
antibodies (in the serum) and JCV-DNA in the urine (Jelcic, Aly et al. 2013). 
However, these two methods do not measure T cell responses. To select HDs based 
on the T cell reactivity to JCV, we therefore used the VP1-peptide pool as stimulus in 
a T cell assay (MLPC). VP1 is one out of five proteins of JCV, which has been 
considered to be highly immunogenic (Jelcic, Aly et al. 2013). Immunogenicity of 
VP1 was also confirmed in studies with BKV in HDs and patients (Kiecker, Streitz et 
al. 2004; Hammer, Brestrich et al. 2006; Ginevri, Azzi et al. 2007; Comoli, Hirsch et 
al. 2008). In this study, considering VP1-protein as the immunological target, we 
performed epitope mapping using an approach displayed in Figure 24.  
JCV-VP1 overlapping peptides and the peptide pool 
In a comprehensive epitope mapping strategy, we used JCV-VP1 overlapping 
peptides as matrix peptide sub-pools in ELISPOT assays (Figure 13). The use of 
overlapping peptides for T cell epitope mapping for other viruses has already been 
reported (Trivedi, Williams et al. 2005; Homann, Lewicki et al. 2007; Schalich, 
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Vytvytska et al. 2008; Wu, Zanker et al. 2011; Walsh, Sidney et al. 2013). In the 
experimental setting, we used 25,000 to 30,000 effector cells stimulated in MLPC 
and the IFN-γ secretion was characterized into weak, moderate and strong T cell 
responses on the basis of S.I. Based on this criteria, we detected JCV-VP1-specific 
CD8+ T cell responses in almost 73% (16 out of 22) of HDs. Our results of JCV-
specific T cell responses were similar to one study where it showed 77.6% positivity 
using VP1-peptide pool (Jelcic, Aly et al. 2013).  
Virus like particles (VLP) 
To study cellular immune responses to JCV-VP1 and to map TCEs, we used VP1-
VLP as primary stimulus. VLP are derived from VP1 and since VP1 constitutes 
almost 80% of the JCV-capsid, VLP shows morphological (Teunissen, de Raad et al. 
2013) and immunological resemblance to the virus in its natural form (Viscidi, 
Rollison et al. 2003; Viscidi and Clayman 2006; Nicol, Touze et al. 2012). Some of 
the previous studies reported the use of polyomavirus-infected cell lysate to study T 
cell responses (Drake, Moser et al. 2000; Li, Melenhorst et al. 2006). Lysate might 
constitute all the proteins present in the virus. However, standardization steps (e.g. 
protein concentration, freeze-thaw etc.) are difficult to be taken and a higher bio-
safety (S2) facility is needed to work with polyomaviruses. On the other hand, VLP 
can be safely used at the S1 level with much less standardization steps. Another big 
advantage using VLP is the selection of naturally processed T cell specificities. While 
using peptides, one might find some specificity which is normally not presented by 
virus-infected cells, VLP on the other hand has to be first internalized and then 
processed by the proteasome machinery into peptides to bind to the HLA class I 
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molecule. In this process, all the resulting T cell determinants presented by HLA 
class I molecules are not artificial but naturally processed.  
Naturally processed TCEs 
An unexpected result was observed in one donor (Table 4, donor#4196) who was 
positive for the 15mer peptide OP76 (LINRRTPRVDGQPMY). In contrast, the 
corresponding 9mer peptide p306 (TPRVDGQPM) predicted to bind with high-affinity 
was unable to stimulate IFN-γ secretions. One obvious reason might be that the 
predicted epitope was not the natural TCE (Eisenlohr, Yewdell et al. 1992). The 
epitope could be a 8mer or 10mer peptide and not a 9mer. In this context, there is 
evidence that some unusually long peptides derived from viral-antigens (12 to 14 
amino acids long) are naturally presented by HLA class I molecules (Schirmbeck, 
Melber et al. 1994; Longmate, York et al. 2001; Green, Miles et al. 2004; Crough, 
Burrows et al. 2005; Pudney, Leese et al. 2005; Tynan, Borg et al. 2005; Tynan, 
Burrows et al. 2005; Burrows, Rossjohn et al. 2006). Moreover, it has been reported 
that 9mers or 10mers which are completely preserved in immunogenic long 
peptides, fail to induce T cell responses despite having high predictive HLA class I 
binding scores. For example, the HLA-A*201 binding p53 nonamer sequence 
(GLAPPQHLI) has a high predictive score but is non-immunogenic. However, the 11-
mer peptide sequence (GLAPPQHLIRV) is comparatively immunogenic (Theobald, 
Biggs et al. 1997). Similar results were reported for 11mer peptide epitopes derived 
from the EBV nuclear antigen 1 (Blake, Lee et al. 1997) and the hepatitis B virus 
(Missale, Redeker et al. 1993). However, to address this question all possible 
permutations of peptides of different length derived from immunogenic 15mer should 
be analyzed.  
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Restriction analysis 
Another important aspect in the identification of TCEs was to perform HLA restricted 
peptide recognition. To this end, HLA-transfectants (K562-A2, K562-B7) and T2 cells 
were used. The use of K562-A2 (Britten, Meyer et al. 2002) and T2 (Schalich, 
Vytvytska et al. 2008) has been shown in earlier reports. Employing HLA-
transfectants in ELISPOT assays was the key step because that way we were 
selecting a particular HLA restricted T cell specificity out of many VLP-stimulated 
HLA class I restricted T cell specificities.    
Immune responses to peptides p36 and p100 
Previously, two CD8+ TCEs (p36 and p100) have been described in HLA-A2 positive 
donors (Koralnik, Du Pasquier et al. 2002; Du Pasquier, Kuroda et al. 2003). Using 
the p100-peptide at different concentrations we characterized T cells with high-
affinity TCR (discussed in 3.3). In our experimental setting, the p100-peptide was 
represented by the 15mer peptide OP25 and matrix sub-pools 5 and 13 (Figure 13). 
The p36-peptide was covered by the 15mer peptide OP9 and matrix sub-pools 9 and 
11. We found CD8+ T cells specific to both immunodominant peptides in more than 
one-third HLA-A2 positive donors (Table 3). The results of JCV were similar to a 
study performed in HLA-A2 positive HDs using the immunodominant BKV peptides 
p44 and p108 (van Aalderen, Remmerswaal et al. 2013).  
New TCEs 
In addition to two known epitopes, we observed several other HLA-A2 and HLA-B7 
restricted T cell specificities (Table 3 and Table 4). Some of them tested positive in 
more than 10% donors, e.g. the HLA-A2 restricted peptides OP28, OP29, OP72, 
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OP78, p113 and the HLA-B7 restricted peptides OP23, OP53, p290, and p83. Out of 
these TCEs, some peptides tested positive in more than 25% of HDs (Table 5). 
Along with p36 and p100-peptides, these peptides can be also considered as 
immunodominant. Of most interest are the two neighbouring overlapping 15mer 
peptides OP28 and OP29 which contain the common 9mer sequence p113 
(IGVTSLMNV). Using this 9mer peptide as stimulus we observed high frequencies of 
positive donors (25%) and strong T cell responses (Table 5).   
HLA-immunodominance 
Regarding the influence of certain HLA-alleles on cellular immune responses, it has 
been observed that an individual who is both HLA-A2 and B7 positive, will show a 
stronger response to the immunogenic epitope restricted to HLA-B7 but not to HLA-
A2, a phenomenon called as relative HLA-dominance where HLA-B7 restricted T cell 
response dominates over the HLA-A2 restricted response. This phenomenon has 
been explored in CMV (Lacey, Villacres et al. 2003), EBV (Hollsberg 2002) and HIV 
(Day, Shea et al. 2001). In our study, only one donor#4195 expressed both HLA-A2 
and HLA-B7. In this donor, we found that there were moderate to high T cell 
responses to HLA-A2 restricted epitopes (p100, p36) while only one HLA-B7-binding 
peptide was found positive. Here, the relative HLA-dominance was not clear. 
Moreover, it was difficult to explain this phenomenon without the knowledge of any 
widely accepted JCV-specific HLA-B7 restricted TCE. Nevertheless, the HLA-
dominance in JCV is not yet reported and it will be interesting to study this 
phenomenon, especially in the Caucasian population where one out of every four 
individuals is both HLA-A2 and HLA-B7 positive.  
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Cross-reactivity and new TCEs using patients’ PBMCs 
A patient, who has already experienced an active phase of infection, is the best 
model to map TCEs, essentially due to the presence of high precursor frequencies of 
virus-specific T cells. We had the opportunity to use blood samples from an HC-
affected patient for TCE mapping. Despite the fact that the patient had experienced 
BKV-induced HC and not PML (JCV-induced), our hypothesis to identify a TCE was 
based on the cross-reactivity of T cells due to high sequence homology between 
these two viruses (Figure 17, 18). For this purpose, we used JCV and BKV-VLP. 
Interestingly, we observed a similar CD8+ T cell response to both types of VLPs. 
Additionally, similar responses were observed to a pool of six predicted HLA-B7-
binding peptides also (Figure 26). In order to find immunogenic peptides present in 
the pool, individual peptides were used after being primarily stimulated with JCV-
VLP. Two individual peptides (p83 and p306) were found positive (Figure 27). The 
9mer peptide p83 was strongly positive in one HD also where it showed high T cell 
responses in three independent experiments (Table 4).   
JCV-specific cellular immunotherapies 
To date, single case of T cell adoptive transfer against JCV-infection has been 
reported (Balduzzi, Lucchini et al. 2011). In vitro activated JCV-specific CTLs were 
introduced in a patient with clinical status of PML who showed great improvement 
after adoptive T cell transfer. In this case report, T cells were activated using peptide 
pool of VP1 and LT-antigen with no enrichment and isolation of virus-specific T cells. 
Bulk T cells, however, might lead to GvHD in immunosuppressed patients due to the 
presence of non-specific T cells. In our study, we defined some CD8+ TCEs and 
4. DISCUSSION 
89 
 
since the stimulation was induced by VLP such TCEs are naturally processed. Most 
importantly, adoptive transfer with viral epitope-specific T cells would greatly 
minimize the risk of GvHD in patients.  
Conclusions 
Identification and characterization of polyomavirus-specific T cell epitopes is a 
prerequisite for the development of both peptide based vaccines and antigen-specific 
T cell therapies. Adoptive T cell transfer has shown promising clinical results for 
some virus-related infections (e.g. CMV, EBV, adenovirus etc.). To this end, we 
exploited a comprehensive strategy including mapping of T cell epitopes using 
overlapping peptides combined with peptide matrix pools and algorithm programs. It 
was demonstrated that two immunodominant HLA-A2 restricted T cell specificities for 
VP1p36 and p100 peptides interact with high avidity and preserve the functional 
integrity for weeks after in vitro culture. Novel, naturally processed T cell epitopes 
were identified and constitute candidates for future cellular immunotherapies. Our 
study focused on HLA-A2 and HLA-B7 alleles and as such covers the majority of the 
Caucasian population. Cross-reactivity, as demonstrated for BKV-and JCV-specific T 
cells, may also facilitate targeting both polyomaviruses-related diseases 
simultaneously.  
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